notes_NNS to_TO the_DT financial_JJ statements_NNS 1_CD Accounting_NN policies_NNS Pension_NN costs_VBZ The_DT costs_NNS of_IN the_DT Groups_NNS defined_VBN contribution_NN pension_NN Accounting_NN convention_NN and_CC presentation_NN arrangements_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN under_IN the_DT historical_JJ year_NN to_TO which_WDT they_PRP relate_VBP ._.
The_DT costs_NNS of_IN the_DT Groups_NNS defined_VBN cost_NN convention_NN and_CC in_IN accordance_NN with_IN the_DT Companies_NNS Act_NNP 1985_CD benefits_NNS scheme_NN are_VBP charged_VBN on_IN a_DT systematic_JJ basis_NN allowing_VBG for_IN and_CC applicable_JJ UK_NNP accounting_NN standards_NNS ._.
The_DT principal_JJ accounting_NN the_DT expected_VBN pension_NN cost_NN over_IN the_DT service_NN lives_NNS of_IN employees_NNS ,_, policies_NNS have_VBP been_VBN applied_VBN consistently_RB and_CC are_VBP set_VBN out_RP below_IN ._.
The_DT results_NNS for_IN the_DT year_NN all_DT relate_VBP to_TO continuing_VBG operations_NNS ._.
The_DT financial_JJ statements_NNS have_VBP been_VBN prepared_VBN on_IN a_DT going_VBG concern_NN basis_NN ._.
Employee_NN share_NN plans_VBZ Incentives_NNS in_IN the_DT form_NN of_IN shares_NNS are_VBP provided_VBN to_TO employees_NNS under_IN Consolidation_NN share_NN option_NN and_CC share_NN award_NN schemes_NNS ._.
In_IN respect_NN of_IN award_NN The_DT consolidated_JJ financial_JJ information_NN includes_VBZ the_DT financial_JJ schemes_NNS the_DT Group_NNP provides_VBZ finance_NN to_TO an_DT employee_NN share_NN statements_NNS for_IN the_DT Company_NN and_CC its_PRP$ subsidiary_NN undertakings_NNS ._.
ownership_NN trust_NN to_TO purchase_VB company_NN shares_NNS on_IN the_DT open_JJ Intra-Group_NNP sales_NNS and_CC profits_NNS are_VBP eliminated_VBN fully_RB on_IN market_NN to_TO meet_VB the_DT Groups_NNS obligation_NN to_TO provide_VB shares_NNS when_WRB consolidation_NN ._.
The_DT results_NNS of_IN subsidiaries_NNS sold_VBN or_CC acquired_VBN are_VBP employees_NNS exercise_VBP their_PRP$ award_NN ._.
The_DT difference_NN between_IN the_DT included_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_VBP up_RP to_TO the_DT purchase_NN price_NN of_IN the_DT shares_NNS and_CC the_DT exercise_NN price_NN of_IN the_DT award_NN date_NN of_IN their_PRP$ sale_NN or_CC from_IN their_PRP$ date_NN of_IN acquisition_NN respectively_RB ._.
is_VBZ charged_VBN ,_, or_CC credited_VBN ,_, to_TO the_DT profit_NN and_CC loss_NN account_NN over_IN the_DT periods_NNS of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT award_NN was_VBD granted_VBN ._.
Revenue_NN recognition_NN Turnover_NN comprises_VBZ contract_NN development_NN and_CC licensing_NN ,_, royalty_NN The_DT costs_NNS of_IN running_VBG the_DT employee_NN share_NN ownership_NN trust_NN are_VBP and_CC manufacturing_NN and_CC distribution_NN income_NN ._.
Contract_NN charged_VBD to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP accrue_VBP ._.
development_NN and_CC licensing_NN income_NN represents_VBZ amounts_NNS invoiced_VBD to_TO customers_NNS for_IN services_NNS rendered_VBN under_IN development_NN and_CC Shares_NNS held_VBN by_IN the_DT employee_NN share_NN ownership_NN trust_NN are_VBP licensing_VBG agreements_NNS ,_, including_VBG milestone_NN payments_NNS and_CC accounted_VBD for_IN as_IN fixed_JJ asset_NN investments_NNS at_IN cost_NN less_JJR accrual_NN for_IN technology_NN access_NN fees_NNS ._.
Contract_NN revenue_NN is_VBZ recognized_VBN when_WRB costs_NNS charged_VBN ._.
earned_VBN and_CC non-refundable_JJ and_CC to_TO the_DT extent_NN that_IN there_EX are_VBP no_DT future_JJ obligations_NNS pursuant_JJ to_TO the_DT revenue_NN ,_, in_IN accordance_NN with_IN Intangible_JJ fixed_JJ assets_NNS the_DT contract_NN terms_NNS ._.
Refundable_JJ contract_NN revenue_NN is_VBZ treated_VBN as_IN Intangible_JJ fixed_JJ assets_NNS comprise_VBP goodwill_NN ,_, intellectual_JJ property_NN deferred_VBN until_IN such_JJ time_NN as_IN it_PRP is_VBZ no_RB longer_RBR refundable_JJ ._.
Royalty_NN and_CC capitalized_JJ development_NN costs_NNS ._.
Goodwill_NNP ,_, being_VBG the_DT income_NN represents_VBZ income_NN earned_VBD as_IN a_DT percentage_NN of_IN product_NN difference_NN between_IN the_DT fair_JJ value_NN of_IN the_DT purchase_NN consideration_NN sales_NNS ._.
Advance_NNP royalties_NNS received_VBD are_VBP treated_VBN as_IN deferred_JJ income_NN and_CC the_DT Groups_NNS share_NN of_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS acquired_VBN ,_, until_IN earned_VBN ,_, when_WRB they_PRP are_VBP recognized_VBN as_IN income_NN ._.
is_VBZ capitalized_VBN and_CC amortised_VBN over_IN a_DT period_NN of_IN 20_CD years_NNS or_CC less_JJR in_IN Manufacturing_NNP and_CC distribution_NN revenues_NNS principally_RB comprise_VBP line_NN with_IN the_DT Directors_NNS view_NN of_IN its_PRP$ useful_JJ economic_JJ life_NN ._.
Prior_RB to_TO contract_NN manufacturing_NN fees_NNS invoiced_VBD to_TO third_JJ parties_NNS and_CC income_NN the_DT introduction_NN of_IN FRS_NNP 10_CD :_: Goodwill_NNP and_CC intangible_JJ assets_NNS ,_, the_DT from_IN product_NN sales_NNS ._.
policy_NN adopted_VBN was_VBD to_TO write_VB off_RP goodwill_NN to_TO reserves_NNS ._.
As_IN permitted_VBN by_IN FRS_NNP 10_CD goodwill_NN written_VBN off_RP to_TO reserves_NNS in_IN previous_JJ years_NNS has_VBZ Research_NN and_CC development_NN costs_NNS not_RB been_VBN reinstated_VBN on_IN the_DT balance_NN sheet_NN and_CC adjustments_NNS to_TO Research_NNP and_CC development_NN costs_NNS are_VBP charged_VBN as_IN an_DT expense_NN in_IN such_JJ goodwill_NN have_VBP been_VBN taken_VBN directly_RB to_TO reserves_NNS ._.
Goodwill_NNP the_DT period_NN in_IN which_WDT they_PRP are_VBP incurred_VBN ._.
previously_RB written_VBN off_RP to_TO reserves_NNS is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT event_NN of_IN disposal_NN of_IN the_DT related_JJ business_NN ._.
Foreign_JJ currency_NN transactions_NNS Foreign_JJ currency_NN transactions_NNS by_IN Group_NNP companies_NNS are_VBP recorded_VBN Intellectual_NNP property_NN comprises_VBZ acquired_VBN patents_NNS ,_, trade_NN marks_NNS ,_, in_IN local_JJ currency_NN at_IN the_DT exchange_NN rate_NN ruling_NN on_IN the_DT date_NN of_IN know-how_NN and_CC other_JJ similarly_RB identified_VBN rights_NNS ._.
Assets_NNS and_CC liabilities_NNS expressed_VBN in_IN foreign_JJ recorded_VBN at_IN their_PRP$ fair_JJ value_NN at_IN acquisition_NN date_NN and_CC are_VBP amortised_VBN currencies_NNS are_VBP translated_VBN into_IN sterling_NN at_IN the_DT exchange_NN rates_NNS in_IN equal_JJ instalments_NNS over_IN their_PRP$ estimated_VBN useful_JJ economic_JJ lives_NNS ,_, ruling_VBG at_IN the_DT balance_NN sheet_NN date_NN ._.
Exchange_NNP differences_NNS which_WDT from_IN the_DT date_NN when_WRB the_DT transfer_NN of_IN technology_NN is_VBZ complete_JJ ._.
The_DT relate_VBP to_TO the_DT retranslation_NN of_IN net_JJ assets_NNS of_IN overseas_JJ companies_NNS period_NN over_IN which_WDT the_DT Group_NNP expects_VBZ to_TO derive_VB economic_JJ benefits_NNS are_VBP taken_VBN directly_RB to_TO reserves_NNS ._.
All_DT other_JJ foreign_JJ exchange_NN does_VBZ not_RB exceed_VB 20_CD years_NNS ._.
Costs_NNS associated_VBN with_IN internally_RB differences_NNS are_VBP taken_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT year_NN in_IN developed_JJ intellectual_JJ property_NN are_VBP generally_RB treated_VBN as_IN research_NN which_WDT they_PRP arise_VBP ._.
The_DT Group_NNP uses_VBZ the_DT average_JJ exchange_NN rates_NNS and_CC development_NN costs_NNS ._.
prevailing_VBG during_IN the_DT year_NN to_TO translate_VB the_DT results_NNS of_IN overseas_JJ subsidiaries_NNS into_IN sterling_NN and_CC year-end_NN rates_NNS to_TO translate_VB the_DT net_JJ assets_NNS of_IN those_DT undertakings_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 58_CD 59_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 1_CD Accounting_NN policies_NNS continued_VBD Convertible_JJ debt_NN On_IN issue_NN ,_, convertible_JJ debt_NN is_VBZ stated_VBN at_IN the_DT amount_NN of_IN net_JJ Tangible_JJ fixed_JJ assets_NNS proceeds_NNS after_IN deducting_VBG issue_NN costs_NNS ._.
On_IN conversion_NN ,_, the_DT amount_NN Tangible_JJ fixed_JJ assets_NNS are_VBP included_VBN in_IN the_DT balance_NN sheet_NN at_IN cost_NN recognized_VBN in_IN shareholders_NNS funds_NNS in_IN respect_NN of_IN the_DT shares_NNS less_RBR accumulated_VBN depreciation_NN ._.
Depreciation_NN is_VBZ provided_VBN on_IN issued_VBN is_VBZ equal_JJ to_TO the_DT carrying_VBG value_NN at_IN the_DT date_NN of_IN conversion_NN ._.
tangible_JJ fixed_JJ assets_NNS at_IN rates_NNS calculated_VBN to_TO write_VB off_RP the_DT cost_NN ,_, less_JJR Interest_NN payable_JJ on_IN convertible_JJ debt_NN is_VBZ calculated_VBN to_TO unwind_VB the_DT estimated_VBN residual_JJ value_NN ,_, of_IN each_DT asset_NN over_IN its_PRP$ expected_VBN useful_JJ issue_NN costs_NNS and_CC any_DT discount_NN on_IN issue_NN at_IN a_DT constant_JJ rate_NN over_IN the_DT life_NN ._.
The_DT rates_NNS and_CC bases_NNS are_VBP as_IN follows_VBZ :_: term_NN of_IN the_DT debt_NN ._.
Freehold_NNP land_NN not_RB depreciated_VBD Deferred_JJ consideration_NN Freehold_NNP buildings_NNS 2_CD %_NN 5_CD %_NN straight_JJ line_NN Provisions_NNS for_IN deferred_JJ consideration_NN comprise_VBP the_DT fair_JJ value_NN of_IN Short_JJ leasehold_NN property_NN period_NN of_IN lease_NN contingent_JJ consideration_NN arising_VBG from_IN acquisitions_NNS ._.
The_DT eventual_JJ Plant_NN ,_, equipment_NN and_CC fixtures_NNS 10_CD %_NN 33_CD %_NN straight_JJ line_NN outcome_NN is_VBZ subject_JJ to_TO the_DT Groups_NNS future_JJ performance_NN and_CC Motor_NNP vehicles_NNS 20_CD %_NN straight_JJ line_NN certain_JJ contractual_JJ terms_NNS ._.
Provisions_NNS are_VBP reviewed_VBN annually_RB by_IN Finance_NNP leases_VBZ period_NN of_IN lease_NN the_DT Directors_NNS ,_, and_CC changes_NNS to_TO the_DT estimated_VBN fair_JJ value_NN of_IN the_DT contingent_JJ consideration_NN are_VBP recorded_VBN as_IN an_DT adjustment_NN to_TO Fixed_JJ asset_NN investments_NNS goodwill_NN or_CC the_DT underlying_JJ asset_NN value_NN ._.
Investments_NNP that_WDT are_VBP held_VBN for_IN continuing_VBG use_NN in_IN the_DT business_NN are_VBP classified_VBN as_IN fixed_JJ asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN Deferred_VBN taxation_NN sheet_NN at_IN cost_NN or_CC Directors_NNS valuation_NN ,_, less_JJR provision_NN for_IN Deferred_JJ taxation_NN is_VBZ provided_VBN on_IN timing_NN differences_NNS which_WDT at_IN the_DT permanent_JJ diminution_NN in_IN value_NN ._.
balance_NN sheet_NN date_NN result_NN in_IN an_DT obligation_NN to_TO pay_VB more_JJR tax_NN or_CC a_DT right_NN to_TO pay_VB less_JJR tax_NN at_IN a_DT future_JJ date_NN ,_, at_IN rates_NNS expected_VBN to_TO apply_VB Impairment_NN of_IN fixed_JJ assets_NNS when_WRB they_PRP crystallise_VBP based_VBN on_IN current_JJ tax_NN rates_NNS and_CC law_NN ._.
The_DT carrying_VBG values_NNS of_IN fixed_JJ assets_NNS are_VBP reviewed_VBN for_IN impairment_NN Deferred_VBN tax_NN assets_NNS are_VBP recognized_VBN to_TO the_DT extent_NN that_IN it_PRP is_VBZ when_WRB there_EX is_VBZ an_DT indication_NN that_IN the_DT assets_NNS may_MD be_VB impaired_VBN ._.
regarded_VBN as_IN more_RBR likely_JJ than_IN not_RB that_IN they_PRP will_MD be_VB recovered_VBN ._.
First_JJ year_NN impairment_NN reviews_NNS are_VBP conducted_VBN for_IN acquired_VBN Deferred_JJ tax_NN assets_NNS and_CC liabilities_NNS are_VBP not_RB discounted_VBN ._.
Impairment_NN is_VBZ determined_VBN by_IN reference_NN to_TO the_DT higher_JJR of_IN net_JJ realisable_JJ value_NN and_CC value_NN in_IN use_NN ,_, Financial_NNP instruments_NNS which_WDT is_VBZ measured_VBN by_IN reference_NN to_TO discounted_JJ future_JJ cash_NN flows_NNS ._.
The_DT Group_NNP uses_VBZ derivative_JJ financial_JJ instruments_NNS to_TO hedge_VB its_PRP$ Any_DT provision_NN for_IN impairment_NN is_VBZ charged_VBN to_TO the_DT profit_NN and_CC loss_NN exposure_NN to_TO fluctuations_NNS in_IN interest_NN and_CC foreign_JJ exchange_NN rates_NNS ._.
account_NN in_IN the_DT year_NN concerned_VBN ._.
Specifically_RB ,_, the_DT Group_NNP uses_VBZ interest_NN rate_NN swaps_NNS ,_, forward_RB currency_NN contracts_NNS and_CC currency_NN options_NNS ._.
Receipts_NNPS and_CC Stock_NNP and_CC work-in-progress_JJ payments_NNS on_IN interest_NN rate_NN swaps_NNS are_VBP recognized_VBN on_IN an_DT accruals_NNS Stock_NN and_CC work-in-progress_NN are_VBP valued_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC basis_NN ,_, over_IN the_DT life_NN of_IN the_DT swap_NN ,_, as_IN an_DT adjustment_NN to_TO interest_NN net_NN realisable_JJ value_NN and_CC calculated_VBN using_VBG the_DT first-in_NN ,_, first-out_JJ payable_JJ ._.
Gains_NNS and_CC losses_NNS on_IN forward_JJ currency_NN contracts_NNS and_CC basis_NN ._.
currency_NN options_NNS are_VBP not_RB recognized_VBN until_IN the_DT period_NN that_IN the_DT foreign_JJ currency_NN exposure_NN is_VBZ recognized_VBN ._.
Option_NN premia_NN are_VBP Current_JJ asset_NN investments_NNS deferred_VBN in_IN the_DT balance_NN sheet_NN and_CC recognized_VBN upon_IN the_DT maturity_NN Investments_NNP held_VBD other_JJ than_IN for_IN continuing_VBG use_NN in_IN the_DT business_NN of_IN the_DT option_NN agreement_NN ._.
are_VBP classified_VBN as_IN current_JJ asset_NN investments_NNS and_CC recorded_VBN in_IN the_DT balance_NN sheet_NN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
Future_JJ requirements_NNS In_IN December_NNP 2003_CD the_DT Urgent_NNP Issues_NNP Task_NNP Force_NNP issued_VBD Abstract_NNP Liquid_NN resources_NNS 38_CD :_: Accounting_NNP for_IN ESOP_NNP trusts_NNS and_CC amended_VBN Abstract_NNP 17_CD :_: Liquid_NN resources_NNS comprise_VBP short-term_JJ bank_NN and_CC commercial_JJ Employee_NN share_NN schemes_NNS relating_VBG to_TO employee_NN share_NN ownership_NN deposits_NNS with_IN a_DT maturity_NN of_IN less_JJR than_IN one_CD year_NN ._.
These_DT requirements_NNS are_VBP effective_JJ for_IN accounting_NN periods_NNS ending_VBG on_IN or_CC after_IN 22_CD June_NNP 2004_CD and_CC will_MD require_VB the_DT Leased_NNP and_CC hired_VBD assets_NNS shares_NNS held_VBN by_IN the_DT ESOT_NNP to_TO be_VB shown_VBN as_IN a_DT deduction_NN from_IN Leasing_NNP agreements_NNS which_WDT transfer_VBP to_TO the_DT Group_NNP substantially_RB shareholders_NNS funds_NNS ._.
The_DT charge_NN to_TO the_DT profit_NN and_CC loss_NN account_VBP all_DT of_IN the_DT risks_NNS and_CC rewards_NNS of_IN ownership_NN of_IN an_DT asset_NN are_VBP treated_VBN will_MD be_VB the_DT difference_NN between_IN the_DT market_NN price_NN and_CC the_DT exercise_NN as_IN finance_NN leases_NNS ._.
The_DT assets_NNS are_VBP included_VBN in_IN tangible_JJ fixed_VBN price_NN at_IN date_NN of_IN grant_NN ._.
assets_NNS and_CC the_DT capital_NN element_NN of_IN amounts_NNS owed_VBN to_TO the_DT finance_NN company_NN at_IN the_DT balance_NN sheet_NN date_NN is_VBZ included_VBN in_IN creditors_NNS as_IN In_IN June_NNP 2002_CD ,_, the_DT Council_NNP of_IN the_DT European_NNP Union_NNP adopted_VBD a_DT amounts_NNS falling_VBG due_JJ either_CC within_IN or_CC after_IN more_JJR than_IN one_CD year_NN ._.
Regulation_NN requiring_VBG listed_VBN companies_NNS in_IN its_PRP$ Member_NNP States_NNPS Repayments_NNPS are_VBP treated_VBN as_IN consisting_VBG of_IN both_DT capital_NN and_CC to_TO prepare_VB consolidated_JJ financial_JJ statements_NNS in_IN accordance_NN interest_NN with_IN the_DT interest_NN element_NN being_VBG charged_VBN to_TO the_DT profit_NN and_CC with_IN International_NNP Financial_NNP Reporting_NNP Standards_NNPS IFRS_NNP from_IN loss_NN account_NN in_IN proportion_NN to_TO the_DT outstanding_JJ obligations_NNS ._.
The_DT first_JJ SkyePharma_NNP Annual_JJ Report_NNP prepared_VBD Payments_NNS under_IN operating_VBG leases_NNS and_CC short-term_JJ hire_NN contracts_NNS under_IN IFRS_NNP will_MD be_VB for_IN the_DT year_NN ending_VBG 31_CD December_NNP 2005_CD ._.
are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN as_IN they_PRP fall_VBP due_JJ ._.
The_DT Group_NNP has_VBZ commenced_VBN a_DT project_NN to_TO convert_VB its_PRP$ principal_JJ financial_JJ reporting_NN from_IN UK_NNP GAAP_NNP to_TO IFRS_NNP ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 2_CD Segmental_JJ analysis_NN The_DT Groups_NNS operations_NNS relate_VBP wholly_RB to_TO one_CD class_NN of_IN business_NN ,_, pharmaceuticals_NNS ._.
Further_JJ analysis_NN of_IN turnover_NN ,_, loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN and_CC net_JJ assets_NNS by_IN geographical_JJ area_NN is_VBZ set_VBN out_RP below_IN ,_, together_RB with_IN an_DT analysis_NN of_IN cost_NN of_IN sales_NNS ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD a_DT Turnover_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN Milestone_NN payments_NNS 24,196_CD 47,736_CD Research_NNP and_CC development_NN costs_NNS recharged_VBD 5,456_CD 7,705_CD 29,652_CD 55,441_CD Royalties_NNS receivable_JJ 18,701_CD 6,751_CD Manufacturing_NNP and_CC distribution_NN 4,799_CD 7,381_CD 53,152_CD 69,573_CD By_IN location_NN of_IN customer_NN :_: UK_NNP 21,327_CD 21,000_CD Europe_NNP 18,027_CD 10,333_CD North_NNP America_NNP 10,289_CD 34,047_CD Rest_VBP of_IN the_DT world_NN 3,509_CD 4,193_CD 53,152_CD 69,573_CD By_IN location_NN of_IN operation_NN :_: Europe_NNP 42,503_CD 34,449_CD North_NNP America_NNP 10,649_CD 35,124_CD 53,152_CD 69,573_CD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD b_NN Cost_NN of_IN sales_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP Contract_NNP development_NN and_CC licensing_NN 12,085_CD 12,649_CD Royalties_NNS payable_JJ 4,707_CD 1,374_CD Manufacturing_NNP and_CC distribution_NN 12,994_CD 10,807_CD 29,786_CD 24,830_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 60_CD 61_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 2_CD Segmental_JJ analysis_NN continued_VBD Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD c_NN Loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 42,983_CD 1,333_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 5,825_CD 7,695_CD Europe_NNP 3,424_CD 7,652_CD North_NNP America_NNP 30,270_CD 4,759_CD Operating_NN loss_NN profit_NN 39,519_CD 4,716_CD Net_JJ interest_NN payable_JJ 3,464_CD 3,383_CD Loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN 42,983_CD 1,333_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD d_SYM Net_JJ assets_NNS By_IN class_NN of_IN business_NN :_: Pharmaceuticals_NNP 86,265_CD 124,270_CD By_IN location_NN of_IN operation_NN :_: UK_NNP 145,727_CD 151,673_CD Europe_NNP 70,739_CD 69,489_CD North_NNP America_NNP 11,277_CD 42,086_CD 86,265_CD 124,270_CD 3_CD Other_JJ operating_NN income_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP provided_VBD a_DT total_NN of_IN $_$ 30_CD million_CD between_IN 2000_CD and_CC 2002_CD ,_, in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS from_IN DepoMorphine_NNP ,_, Xatral_NNP OD_NNP ,_, Solaraze_NNP and_CC DepoCyt_NNP ._.
Paul_NNP Capital_NNP will_MD receive_VB 15_CD %_NN of_IN the_DT annual_JJ royalties_NNS and_CC revenues_NNS from_IN the_DT stated_VBN products_NNS up_IN to_TO a_DT predetermined_VBN ceiling_NN for_IN the_DT period_NN until_IN 31_CD December_NNP 2014_CD ._.
Once_RB the_DT predetermined_VBN ceiling_NN is_VBZ reached_VBN ,_, the_DT percentage_NN participation_NN will_MD fall_VB to_TO 3_CD %_NN for_IN the_DT remainder_NN of_IN the_DT period_NN until_IN 31_CD December_NNP 2014_CD ._.
Income_NN of_IN 1.1_CD million_CD 2002_CD :_: 9.7_CD million_CD was_VBD recognized_VBN as_IN Other_JJ operating_NN income_NN under_IN this_DT agreement_NN on_IN a_DT cost_NN to_TO complete_VB basis_NN ._.
All_DT of_IN the_DT income_NN under_IN this_DT agreement_NN has_VBZ now_RB been_VBN recognized_VBN ._.
Royalty_NN payments_NNS to_TO Paul_NNP Capital_NNP of_IN 1.0_CD million_CD 2002_CD :_: Nil_NNP have_VBP been_VBN expensed_VBN during_IN the_DT year_NN ._.
Under_IN a_DT second_JJ transaction_NN Paul_NNP Capital_NNP provided_VBD a_DT further_JJ $_$ 30_CD million_CD during_IN 2002_CD and_CC 2003_CD ,_, in_IN return_NN for_IN the_DT sale_NN of_IN a_DT portion_NN of_IN the_DT potential_JJ future_NN royalty_NN and_CC revenue_NN streams_NNS from_IN nine_CD products_NNS from_IN the_DT Groups_NNS drug_NN pipeline_NN ._.
Paul_NNP Capital_NNP will_MD receive_VB between_IN 4_CD %_NN and_CC 20_CD %_NN of_IN the_DT annual_JJ royalties_NNS and_CC revenues_NNS from_IN the_DT nine_CD products_NNS up_IN to_TO a_DT predetermined_VBN ceiling_NN for_IN the_DT period_NN until_IN 31_CD December_NNP 2015_CD ._.
The_DT 20_CD %_NN rate_NN applies_VBZ first_RB and_CC the_DT percentage_NN then_RB falls_VBZ ,_, when_WRB an_DT agreed_VBN ceiling_NN is_VBZ reached_VBN ,_, to_TO 12.5_CD %_NN until_IN a_DT second_JJ ceiling_NN is_VBZ reached_VBN ,_, before_IN falling_VBG to_TO 4_CD %_NN for_IN the_DT remainder_NN of_IN the_DT period_NN until_IN 31_CD December_NNP 2015_CD ._.
During_IN 2002_CD and_CC 2003_CD the_DT 20_CD %_NN rate_NN was_VBD reduced_VBN based_VBN on_IN the_DT percentage_NN of_IN the_DT total_JJ $_$ 30_CD million_CD that_WDT had_VBD been_VBN provided_VBN ._.
Income_NN of_IN 5.0_CD million_CD 2002_CD :_: 4.5_CD million_CD was_VBD recognized_VBN as_IN Other_JJ operating_NN income_NN under_IN this_DT agreement_NN on_IN a_DT cost_NN to_TO complete_VB basis_NN ._.
Royalty_NN payments_NNS to_TO Paul_NNP Capital_NNP of_IN 2.2_CD million_CD 2002_CD :_: 0.7_CD million_CD have_VBP been_VBN expensed_VBN during_IN the_DT year_NN ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 4_CD Exceptional_JJ items_NNS The_DT operating_NN exceptional_JJ items_NNS included_VBD within_IN administration_NN expenses_NNS are_VBP categorised_VBN as_IN follows_VBZ :_: 000_CD Restructuring_NN costs_NNS 2,673_CD Impairment_NN of_IN intellectual_JJ property_NN 2,673_CD Impairment_NN of_IN tangible_JJ fixed_JJ assets_NNS 1,324_CD Write_VB down_IN of_IN fixed_JJ asset_NN investments_NNS 1,599_CD Settlement_NNP of_IN licensing_NN dispute_NN 1,218_CD 9,487_CD The_DT exceptional_JJ charge_NN includes_VBZ 2.7_CD million_CD relating_VBG to_TO the_DT reorganisation_NN of_IN some_DT research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS ,_, involving_VBG some_DT staff_NN redundancies_VBZ at_IN most_JJS sites_NNS ._.
The_DT reorganisation_NN is_VBZ expected_VBN to_TO be_VB completed_VBN during_IN 2004_CD ._.
A_DT further_JJ 4.0_CD million_CD is_VBZ in_IN respect_NN of_IN the_DT impairment_NN of_IN associated_VBN intellectual_JJ property_NN and_CC tangible_JJ fixed_VBN assets_NNS ._.
In_IN addition_NN ,_, 1.6_CD million_CD relates_VBZ to_TO a_DT write_VB down_RP in_IN value_NN of_IN fixed_JJ asset_NN investments_NNS ._.
5_CD Operating_NN loss_NN profit_NN Operating_NN loss_NN profit_NN is_VBZ stated_VBN after_IN charging_VBG :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS owned_VBN assets_NNS 5,704_CD 5,616_CD assets_NNS held_VBN under_IN finance_NN leases_NNS 590_CD 485_CD Amortisation_NNP of_IN intangible_JJ fixed_JJ assets_NNS amortisation_NN of_IN goodwill_NN 4,072_CD 3,799_CD amortisation_NN of_IN intellectual_JJ property_NN 2,379_CD 2,483_CD Research_NNP and_CC development_NN expenses_NNS current_JJ year_NN expenditure_NN 30,520_CD 29,285_CD amortisation_NN of_IN deferred_VBN expenditure_NN 218_CD 224_CD Operating_NN lease_NN rentals_NNS hire_VB of_IN plant_NN and_CC machinery_NN 86_CD 434_CD other_JJ 3,405_CD 3,336_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 62_CD 63_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 5_CD Operating_NN profit_NN loss_NN continued_VBD Services_NNP provided_VBN by_IN the_DT Groups_NNS auditor_NN and_CC network_NN firms_NNS It_PRP is_VBZ the_DT Groups_NNS policy_NN to_TO employ_VB the_DT auditors_NNS on_IN assignments_NNS additional_JJ to_TO their_PRP$ statutory_JJ audit_NN duties_NNS where_WRB their_PRP$ expertise_NN and_CC experience_NN with_IN the_DT Group_NNP are_VBP important_JJ ,_, principally_RB tax_NN advice_NN and_CC due_JJ diligence_NN reporting_VBG on_IN acquisitions_NNS ,_, or_CC where_WRB they_PRP are_VBP awarded_VBN assignments_NNS on_IN a_DT competitive_JJ basis_NN ._.
During_IN the_DT year_NN the_DT Group_NNP including_VBG its_PRP$ overseas_JJ subsidiaries_NNS obtained_VBD the_DT following_JJ services_NNS from_IN the_DT Groups_NNS auditor_NN at_IN costs_NNS detailed_VBN below_IN :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Audit_NNP services_NNS statutory_JJ audit_NN 326_CD 354_CD audit_NN related_VBN regulatory_JJ reporting_NN 145_CD 160_CD Further_JJ assurance_NN services_NNS 227_CD 418_CD Tax_NNP services_NNS compliance_NN services_NNS 228_CD 86_CD advisory_JJ services_NNS 523_CD 595_CD Other_JJ services_NNS not_RB covered_VBN above_IN 25_CD 1,474_CD 1,613_CD Included_VBN in_IN the_DT analysis_NN above_IN are_VBP Group_NNP audit_NN fees_NNS paid_VBN to_TO the_DT Groups_NNS auditor_NN of_IN 160,000_CD 2002_CD :_: 194,000_CD of_IN which_WDT 13,000_CD 2002_CD :_: 13,000_CD was_VBD paid_VBN in_IN respect_NN of_IN the_DT parent_NN company_NN ._.
Also_RB included_VBN above_IN are_VBP fees_NNS paid_VBN to_TO the_DT Groups_NNS auditor_NN in_IN respect_NN of_IN non-audit_JJ services_NNS in_IN the_DT UK_NNP of_IN 710,000_CD 2002_CD :_: 990,000_CD ._.
6_CD Employees_NNS Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Employment_NNP costs_NNS :_: Wages_NNS and_CC salaries_NNS 22,511_CD 20,614_CD Social_NNP security_NN costs_NNS 3,441_CD 3,091_CD Pension_NN costs_NNS 1,769_CD 1,525_CD 27,721_CD 25,230_CD The_DT average_NN monthly_JJ number_NN of_IN persons_NNS employed_VBN by_IN the_DT Group_NNP including_VBG Executive_NNP Directors_NNS during_IN the_DT year_NN was_VBD as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Pharmaceuticals_NNP 476_CD 492_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 7_CD Interest_NN payable_JJ Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Interest_NN payable_JJ on_IN bank_NN loans_NNS ,_, overdrafts_NNS and_CC other_JJ loans_NNS :_: Repayable_JJ within_IN five_CD years_NNS ,_, not_RB by_IN instalments_NNS 93_CD 88_CD Repayable_JJ within_IN five_CD years_NNS ,_, by_IN instalments_NNS 365_CD 112_CD Repayable_JJ wholly_RB or_CC partly_RB in_IN more_JJR than_IN five_CD years_NNS 26_CD 373_CD Finance_NNP leases_NNS 70_CD 130_CD Interest_NN on_IN convertible_JJ bonds_NNS 3,939_CD 3,761_CD 4,493_CD 4,464_CD 8_CD Taxation_NNP Loss_NN profit_NN on_IN ordinary_JJ activities_NNS before_IN taxation_NN ,_, as_IN shown_VBN in_IN the_DT consolidated_JJ profit_NN and_CC loss_NN account_NN ,_, is_VBZ analyzed_VBN between_IN its_PRP$ component_NN parts_NNS as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD UK_NNP 821_CD 146_CD Overseas_JJ 42,162_CD 1,187_CD 42,983_CD 1,333_CD Taxation_NNP charge_NN based_VBN on_IN loss_NN profit_NN for_IN the_DT year_NN :_: Overseas_NNP taxation_NN 240_CD 224_CD Overseas_JJ taxation_NN relates_VBZ principally_RB to_TO withholding_VBG tax_NN paid_VBN on_IN remittance_NN of_IN royalties_NNS to_TO Switzerland_NNP which_WDT is_VBZ not_RB recoverable_JJ ._.
There_EX was_VBD no_DT deferred_JJ tax_NN component_NN in_IN the_DT tax_NN charge_NN for_IN the_DT years_NNS presented_VBN ._.
The_DT Group_NNP has_VBZ estimated_VBN total_JJ tax_NN losses_NNS available_JJ to_TO be_VB set_VBN off_RP against_IN future_JJ taxable_JJ profits_NNS of_IN 211.3_CD million_CD 31_CD December_NNP 2002_CD :_: 178.9_CD million_CD ._.
These_DT losses_NNS arise_VBP primarily_RB in_IN the_DT UK_NNP ,_, Switzerland_NNP and_CC US_NNP ._.
Of_IN the_DT 211.3_CD million_CD of_IN losses_NNS carried_VBD forward_RB ,_, 6.4_CD million_CD expire_VBP in_IN 2004_CD ,_, 61.6_CD million_CD expire_VBP between_IN 2005_CD and_CC 2007_CD ,_, 136.4_CD million_CD expire_VBP from_IN 2008_CD onwards_NNS and_CC 6.9_CD million_CD of_IN losses_NNS may_MD be_VB carried_VBN forward_RB indefinitely_RB ._.
The_DT above_IN charges_NNS reconcile_VBP with_IN the_DT applicable_JJ UK_NNP statutory_JJ corporation_NN tax_NN rate_NN as_IN follows_VBZ :_: Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD %_NN %_NN Statutory_NNP UK_NNP Corporation_NNP tax_NN rate_NN 30.0_CD 30.0_CD Tax_NNP rate_NN differences_NNS 5.9_CD 18.2_CD Permanent_JJ differences_NNS 1.2_CD 19.1_CD Tax_NNP losses_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 22.1_CD 23.6_CD Other_JJ items_NNS not_RB recognized_VBN as_IN deferred_JJ tax_NN assets_NNS 13.2_CD 26.9_CD Effective_JJ tax_NN rate_NN 0.6_CD 16.8_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 64_CD 65_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 9_CD Earnings_NNS per_IN Ordinary_NNP Share_NNP Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Attributable_JJ loss_NN profit_NN before_IN exceptional_JJ items_NNS and_CC amortisation_NN 27,067_CD 7,615_CD Exceptional_JJ items_NNS 9,487_CD Amortisation_NNP 6,669_CD 6,506_CD Basic_JJ and_CC diluted_JJ attributable_JJ loss_NN profit_NN 43,223_CD 1,109_CD 000_CD 000_CD Basic_JJ weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 609,855_CD 577,018_CD Dilution_NN for_IN potential_JJ Ordinary_NNP Shares_NNP 20,077_CD Diluted_NNP weighted_JJ average_JJ number_NN of_IN shares_NNS in_IN issue_NN 609,855_CD 597,095_CD Earnings_NNS per_IN Ordinary_NNP Share_NN before_IN exceptional_JJ items_NNS and_CC amortisation_NN 4.4_CD p_NN 1.3_CD p_NN Exceptional_JJ items_NNS 1.6_CD p_NN Amortisation_NNP 1.1_CD p_NN 1.1_CD p_NN Basic_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP 7.1_CD p_JJ 0.2_CD p_NN Diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NNP 7.1_CD p_JJ 0.2_CD p_NN In_IN 2003_CD there_EX is_VBZ no_DT difference_NN between_IN basic_JJ and_CC diluted_JJ earnings_NNS per_IN Ordinary_NNP Share_NNP since_IN all_DT potential_JJ Ordinary_NNP Shares_NNP including_VBG convertible_JJ bonds_NNS ,_, warrants_NNS and_CC options_NNS are_VBP anti-dilutive_JJ ._.
For_IN diluted_VBN earnings_NNS per_IN Ordinary_NNP Share_NN in_IN 2002_CD ,_, the_DT weighted_JJ average_JJ number_NN of_IN Ordinary_NNP Shares_NNP in_IN issue_NN is_VBZ adjusted_VBN to_TO assume_VB conversion_NN of_IN all_DT dilutive_JJ potential_JJ Ordinary_NNP Shares_NNP ._.
Shares_NNS held_VBN by_IN SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP are_VBP excluded_VBN from_IN the_DT weighted_JJ average_JJ number_NN of_IN shares_NNS ._.
The_DT 2.2_CD million_CD $_$ 3.5_CD million_CD paid_VBN to_TO Enzon_NNP for_IN access_NN to_TO its_PRP$ PEG_NNP modification_NN technology_NN during_IN the_DT year_NN has_VBZ been_VBN recorded_VBN within_IN intellectual_JJ property_NN ._.
Tangible_JJ fixed_JJ assets_NNS include_VBP net_JJ book_NN value_NN of_IN 2,011,000_CD 31_CD December_NNP 2002_CD :_: 2,384,000_CD in_IN respect_NN of_IN assets_NNS held_VBN under_IN finance_NN leases_NNS and_CC hire_VB purchase_NN contracts_NNS ._.
This_DT comprises_VBZ 1,865,000_CD in_IN respect_NN of_IN laboratory_NN equipment_NN and_CC machines_NNS ,_, 19,000_CD in_IN respect_NN of_IN office_NN and_CC other_JJ equipment_NN and_CC 127,000_CD in_IN respect_NN of_IN motor_NN vehicles_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 66_CD 67_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 11_CD Tangible_JJ fixed_VBN assets_NNS continued_VBD Office_NNP and_CC Land_NNP and_CC other_JJ Motor_NNP buildings_NNS equipment_NN vehicles_NNS Total_JJ Company_NN 000 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2003 107 332_CD 75_CD 514_CD Additions_NNS 117_CD 18_CD Disposals_NNPS 75_CD 75_CD At_IN 31_CD December_NNP 2003 108 349 457_CD Depreciation_NNP At_IN 1_CD January_NNP 2003_CD 76_CD 229_CD 75_CD 380_CD Charge_NNP for_IN the_DT year_NN 11_CD 37_CD 48_CD Disposals_NNPS 75_CD 75_CD At_IN 31_CD December_NNP 2003 87 266 353_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2002 31 103 134_CD Net_JJ book_NN value_NN at_IN 31_CD December_NNP 2003_CD 21_CD 83_CD 104_CD 12_CD Fixed_VBN asset_NN investments_NNS a_DT Group_NNP Unlisted_NNP investments_NNS Own_JJ shares_NNS Total_JJ 000 000 000_CD Cost_NN At_IN 1_CD January_NNP 2003_CD 18,874_CD 1,028_CD 19,902_CD Exchange_NNP adjustments_NNS 87_CD 87_CD Additions_NNS 4,836_CD 925_CD 5,761_CD Charge_NNP for_IN the_DT year_NN 558_CD 558_CD Write_VB down_RP note_NN 4_CD 1,599_CD 1,599_CD At_IN 31_CD December_NNP 2003_CD 22,024_CD 1,395_CD 23,419_CD Astralis_NNP Limited_NNP Astralis_NNP is_VBZ an_DT emerging_VBG biotechnology_NN company_NN based_VBN in_IN the_DT US_NNP ,_, and_CC engaged_VBD primarily_RB in_IN the_DT research_NN and_CC development_NN of_IN novel_NN treatments_NNS for_IN immune_JJ system_NN disorders_NNS and_CC skin_NN diseases_NNS ._.
The_DT company_NN is_VBZ currently_RB developing_VBG two_CD products_NNS ._.
Its_PRP$ primary_JJ product_NN ,_, Psoraxine_NNP ,_, is_VBZ an_DT innovative_JJ vaccine_NN under_IN development_NN for_IN the_DT treatment_NN of_IN psoriasis_NN ._.
The_DT companys_NNS second_JJ product_NN is_VBZ for_IN the_DT treatment_NN of_IN leishmaniasis_NN ._.
During_IN the_DT year_NN the_DT Group_NNP acquired_VBD 250,000_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS of_IN Astralis_NNP for_IN 1.5_CD million_CD $_$ 2.5_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 2_CD million_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS ,_, 200,000_CD common_JJ shares_NNS and_CC 20,000_CD warrants_NNS ,_, representing_VBG approximately_RB 25.4_CD %_NN of_IN the_DT common_JJ shares_NNS assuming_VBG conversion_NN of_IN the_DT preferred_JJ shares_NNS and_CC warrants_NNS ._.
The_DT investment_NN is_VBZ not_RB regarded_VBN as_IN an_DT associated_VBN undertaking_NN as_IN the_DT Directors_NNS have_VBP concluded_VBN that_IN the_DT Group_NNP does_VBZ not_RB exercise_VB significant_JJ influence_NN ._.
The_DT convertible_JJ preferred_JJ shares_NNS ,_, common_JJ shares_NNS and_CC warrants_NNS are_VBP recorded_VBN at_IN a_DT cost_NN of_IN 14.2_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2003_CD Astralis_NNP had_VBD net_JJ assets_NNS of_IN 3.5_CD million_CD 31_CD December_NNP 2002_CD :_: 4.9_CD million_CD and_CC a_DT retained_VBN loss_NN for_IN the_DT year_NN of_IN 3.1_CD million_CD 2002_CD :_: 12.2_CD million_CD ._.
In_IN January_NNP 2004_CD SkyePharma_NNP converted_VBD all_DT of_IN its_PRP$ 2_CD million_CD series_NN A_DT convertible_JJ preferred_JJ shares_NNS into_IN 25_CD million_CD common_JJ shares_NNS ,_, 12.5_CD million_CD of_IN these_DT being_VBG held_VBN in_IN escrow_NN ._.
The_DT resulting_VBG holding_NN represents_VBZ approximately_RB 35.7_CD %_NN of_IN the_DT common_JJ shares_NNS ._.
Micap_NNP plc_NN Micap_NNP is_VBZ a_DT UK_NNP science-based_JJ technology_NN company_NN which_WDT was_VBD listed_VBN on_IN the_DT Alternative_NNP Investment_NNP Market_NNP in_IN August_NNP 2003_CD ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 12_CD Fixed_VBN asset_NN investments_NNS continued_VBD During_IN the_DT year_NN the_DT Group_NNP acquired_VBD 5,238,334_CD ordinary_JJ shares_NNS ,_, representing_VBG approximately_RB 18.2_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ,_, and_CC 1,830,000_CD convertible_JJ shares_NNS of_IN Micap_NNP for_IN 2.1_CD million_CD ._.
The_DT shares_NNS are_VBP recorded_VBN at_IN cost_NN ._.
Transition_NN Therapeutics_NNPS Inc_NNP Transition_NN Therapeutics_NNS is_VBZ a_DT biopharmaceutical_JJ company_NN based_VBN in_IN Canada_NNP and_CC engaged_VBN primarily_RB in_IN the_DT business_NN of_IN developing_VBG products_NNS for_IN the_DT treatment_NN of_IN multiple_JJ sclerosis_NN ,_, diabetes_NN and_CC restenosis_NN ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT total_JJ SkyePharma_NNP holding_NN of_IN Transition_NN Therapeutics_NNS was_VBD 4,930,814_CD shares_NNS ,_, representing_VBG approximately_RB 6.6_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT shares_NNS are_VBP recorded_VBN at_IN a_DT net_JJ cost_NN of_IN 0.6_CD million_CD ._.
Vital_JJ Living_VBG Inc_NNP Vital_NNP Living_VBG primarily_RB develops_VBZ and_CC markets_VBZ evidence-based_JJ nutriceuticals_NNS ._.
These_DT are_VBP developed_VBN for_IN incorporation_NN by_IN physicians_NNS into_IN a_DT standard_JJ physician_NN patient_NN program_NN ,_, supported_VBN by_IN a_DT specially_RB designed_VBN compliance_NN regimen_NN ._.
Vital_JJ Living_VBG is_VBZ based_VBN in_IN the_DT US_NNP ._.
At_IN 31_CD December_NNP 2002_CD SkyePharma_NNP held_VBD 1_CD million_CD convertible_JJ preference_NN shares_NNS in_IN e-nutriceuticals_NNS Inc_NNP ,_, based_VBN in_IN the_DT US_NNP ,_, representing_VBG approximately_RB 14.2_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN assuming_VBG conversion_NN ._.
In_IN August_NNP 2003_CD e-nutriceuticals_NNS merged_VBN with_IN Vital_JJ Living_VBG and_CC as_IN a_DT result_NN of_IN the_DT merger_NN SkyePharma_NNP acquired_VBD 14,204,548_CD common_JJ shares_NNS in_IN Vital_JJ Living_VBG ._.
During_IN the_DT year_NN the_DT Group_NNP acquired_VBD 1_CD million_CD series_NN D_NNP convertible_JJ preferred_JJ shares_NNS ,_, $_$ 1_CD million_CD of_IN 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS due_JJ 2008_CD and_CC 1_CD million_CD warrants_NNS expiring_VBG 2008_CD of_IN Vital_JJ Living_VBG for_IN 1.2_CD million_CD $_$ 2.0_CD million_CD ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT total_JJ SkyePharma_NNP holding_NN was_VBD 14,204,548_CD common_JJ shares_NNS ,_, 1_CD million_CD series_NN D_NNP convertible_JJ preferred_JJ shares_NNS ,_, $_$ 1_CD million_CD 12_CD %_NN senior_JJ secured_VBN convertible_JJ notes_NNS due_JJ 2008_CD and_CC 1_CD million_CD warrants_NNS expiring_VBG 2008_CD ,_, representing_VBG approximately_RB 24.4_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ,_, 28.1_CD %_NN assuming_VBG conversion_NN of_IN the_DT preferred_JJ shares_NNS ,_, notes_NNS and_CC warrants_NNS ._.
The_DT investment_NN is_VBZ recorded_VBN at_IN 5.1_CD million_CD ,_, comprising_VBG shares_NNS recorded_VBN at_IN Directors_NNS valuation_NN based_VBN on_IN a_DT number_NN of_IN considerations_NNS including_VBG comparable_JJ transactions_NNS and_CC discounted_JJ future_JJ cash_NN flows_NNS ,_, and_CC notes_NNS and_CC warrants_NNS recorded_VBN at_IN cost_NN ._.
The_DT most_RBS recent_JJ accounts_NNS available_JJ are_VBP as_RB at_IN 30_CD September_NNP 2003_CD when_WRB Vital_JJ Living_VBG had_VBD net_JJ assets_NNS of_IN 27.8_CD million_CD and_CC a_DT retained_VBN loss_NN for_IN the_DT nine_CD month_NN period_NN of_IN 10.1_CD million_CD ._.
Cade_NNP Struktur_NNP Corp._NNP ._.
Cade_NNP Struktur_NNP was_VBD formerly_RB a_DT drug_NN delivery_NN company_NN engaged_VBD in_IN research_NN and_CC development_NN and_CC worldwide_JJ commercialisation_NN of_IN pharmaceutical_JJ formulations_NNS ._.
The_DT current_JJ business_NN is_VBZ the_DT development_NN ,_, financing_NN and_CC completion_NN of_IN industrial_JJ and_CC infrastructure_NN projects_NNS in_IN Europe_NNP ._.
As_IN at_IN 31_CD December_NNP 2003_CD ,_, the_DT total_JJ SkyePharma_NNP holding_NN of_IN Cade_NNP Struktur_NNP ,_, a_DT Canadian_JJ company_NN ,_, was_VBD 869,086_CD shares_NNS ,_, representing_VBG approximately_RB 10.1_CD %_NN of_IN the_DT ordinary_JJ share_NN capital_NN ._.
The_DT shares_NNS were_VBD originally_RB acquired_VBN consequent_JJ upon_IN the_DT acquisition_NN of_IN the_DT assets_NNS of_IN Hyal_NNP Pharmaceutical_NNP Corp._NNP ._.
SkyePharma_NNP has_VBZ not_RB attributed_VBN a_DT value_NN to_TO these_DT shares_NNS and_CC they_PRP have_VBP been_VBN recorded_VBN at_IN zero_CD cost_NN ._.
Own_JJ shares_NNS During_IN 2001_CD the_DT Company_NN established_VBD an_DT employee_NN share_NN ownership_NN trust_NN ,_, the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP Trust_NNP ._.
The_DT purpose_NN of_IN the_DT trust_NN is_VBZ to_TO hold_VB shares_NNS in_IN the_DT Company_NN ,_, which_WDT may_MD subsequently_RB be_VB awarded_VBN to_TO Directors_NNS and_CC employees_NNS under_IN the_DT Deferred_NNP Share_NNP Bonus_NNP Plan_NNP and_CC Share_NNP Purchase_NNP Plans_NNP ._.
Further_JJ details_NNS of_IN this_DT plan_NN are_VBP provided_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
During_IN the_DT year_NN ,_, the_DT trust_NN purchased_VBD 2_CD million_CD shares_NNS and_CC approximately_RB 1.1_CD million_CD shares_NNS were_VBD allocated_VBN at_IN an_DT average_JJ price_NN of_IN 51_CD pence_NN per_IN share_NN ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT trust_NN held_VBD approximately_RB 2.7_CD million_CD shares_NNS at_IN a_DT carrying_VBG value_NN of_IN 1.4_CD million_CD and_CC a_DT market_NN value_NN of_IN 2.1_CD million_CD ._.
b_NN Company_NN Shares_NNS in_IN Loans_NNS to_TO Group_NNP Group_NNP Unlisted_NNP Own_NNP undertakings_NNS undertakings_NNS investments_NNS shares_NNS Total_JJ 000 000 000 000_CD 000_CD At_IN 1_CD January_NNP 2003_CD 202,176_CD 181,311_CD 12,696_CD 1,028_CD 397,211_CD Additions_NNPS 2,713_CD 18,000_CD 3,636_CD 925_CD 25,274_CD Capitalisation_NNP of_IN loans_NNS 4,993_CD 4,993_CD Charge_NNP for_IN the_DT year_NN 558_CD 558_CD At_IN 31_CD December_NNP 2003_CD 209,882_CD 194,318_CD 16,332_CD 1,395_CD 421,927_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 68_CD 69_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 13_CD Stock_NNP Group_NNP Group_NNP 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Raw_NNP materials_NNS and_CC consumables_NNS 981_CD 919_CD Work_NN in_IN progress_NN 266_CD 263_CD Finished_VBN goods_NNS 73_CD 74_CD 1,320_CD 1,256_CD The_DT replacement_NN cost_NN of_IN stock_NN is_VBZ not_RB materially_RB different_JJ from_IN original_JJ cost_NN ._.
14_CD Debtors_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000 000_CD 000_CD Trade_NNP debtors_NNS 2,800_CD 26,327_CD Amounts_NNPS owed_VBN by_IN subsidiary_NN undertakings_NNS 5,481_CD 24,310_CD Other_JJ debtors_NNS 2,953_CD 2,224_CD 103_CD 122_CD Prepayments_NNS and_CC accrued_VBN income_NN 9,745_CD 6,502_CD 728_CD 1,465_CD Interest_NN receivable_NN 136 154 136 154_CD 15,634_CD 35,207_CD 6,448_CD 26,051_CD 15_CD Current_JJ Asset_NNP Investments_NNP Current_JJ asset_NN investments_NNS are_VBP represented_VBN by_IN 5_CD %_NN convertible_JJ loan_NN notes_NNS due_JJ at_IN par_NN ,_, together_RB with_IN accrued_VBN interest_NN in_IN June_NNP 2007_CD ._.
The_DT notes_NNS were_VBD received_VBN from_IN GeneMedix_NNP plc_NN in_IN 2002_CD as_IN an_DT initial_JJ payment_NN under_IN an_DT agreement_NN to_TO jointly_RB develop_VB an_DT extended_JJ release_NN formulation_NN of_IN Interferon_NNP alpha-2b_JJ using_VBG SkyePharmas_NNP DepoFoam_NNP technology_NN ._.
The_DT notes_NNS are_VBP convertible_JJ at_IN any_DT time_NN ,_, at_IN SkyePharmas_NNP option_NN ,_, into_IN between_IN approximately_RB 8.3_CD million_CD and_CC 11.2_CD million_CD GeneMedix_NNP ordinary_JJ shares_NNS ._.
There_EX are_VBP no_DT restrictions_NNS or_CC a_DT lock-up_JJ period_NN on_IN conversion_NN of_IN the_DT notes_NNS ._.
GeneMedix_NNP can_MD elect_VB to_TO redeem_VB in_IN cash_NN some_DT or_CC all_DT of_IN the_DT notes_NNS on_IN conversion_NN ._.
The_DT notes_NNS have_VBP been_VBN recorded_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN assuming_VBG conversion_NN ._.
16_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000 000_CD 000_CD Bank_NNP overdrafts_NNS 1,198_CD Current_JJ portion_NN of_IN bank_NN loans_NNS note_VBP 17_CD 2,342_CD 1,572_CD 761_CD Current_JJ portion_NN of_IN secured_JJ mortgage_NN note_NN 17 271 270_CD Chiron_NNP promissory_JJ note_NN 559_CD Trade_NNP creditors_NNS 5,915_CD 3,344_CD 337_CD 69_CD Amounts_NNS owed_VBN to_TO subsidiary_NN undertakings_NNS 9,639_CD 10,229_CD Corporation_NNP tax_NN 3_CD 3_CD Other_JJ taxation_NN and_CC social_JJ security_NN costs_NNS 1,628_CD 893_CD 221_CD 83_CD Obligations_NNS under_IN hire_NN purchase_NN and_CC finance_NN leases_NNS 160_CD 1,085_CD Deferred_JJ income_NN 12,926_CD 15,069_CD Accruals_NNPS 14,318_CD 12,235_CD 3,574_CD 3,431_CD 39,320_CD 34,471_CD 14,532_CD 13,812_CD At_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD loans_NNS with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 0.9_CD million_CD CHF_NNP 2_CD million_CD and_CC 0.7_CD million_CD CHF_NNP 1.5_CD million_CD ._.
These_DT loans_NNS are_VBP renewable_JJ annually_RB and_CC bear_VB interest_NN at_IN 6.5_CD %_NN and_CC 6.0_CD %_NN respectively_RB ._.
The_DT loans_NNS are_VBP secured_VBN on_IN the_DT assets_NNS of_IN Jago_NNP and_CC are_VBP guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
At_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD a_DT promissory_JJ note_NN with_IN Chiron_NNP of_IN 0.6_CD million_CD $_$ 1_CD million_CD which_WDT formed_VBD part_NN of_IN the_DT consideration_NN for_IN the_DT reacquisition_NN of_IN the_DT US_NNP DepoCyt_NNP marketing_NN ,_, distribution_NN and_CC sales_NNS rights_NNS ._.
The_DT promissory_JJ note_NN is_VBZ repayable_JJ in_IN June_NNP 2004_CD ,_, bearing_VBG interest_NN at_IN LIBOR_NNP plus_CC 300_CD points_NNS and_CC is_VBZ guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 17_CD Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000 000_CD 000_CD Bank_NNP loans_NNS 1,923_CD 1,923_CD Secured_JJ mortgage_NN 7,272_CD 7,502_CD Chiron_NNP promissory_JJ note_NN 621_CD Accrued_VBN rent_NN 3,459_CD 3,269_CD Convertible_JJ bonds_NNS due_JJ 2005_CD 58,791_CD 58,377_CD 58,791_CD 58,377_CD Deferred_JJ income_NN 2,948_CD 2,960_CD Obligations_NNS under_IN finance_NN leases_NNS 206_CD 235_CD 74,599_CD 72,964_CD 60,714_CD 58,377_CD Bank_NNP and_CC other_JJ loans_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 1,171_CD 5,158_CD 900_CD Between_IN two_CD and_CC three_CD years_NNS 1,247_CD 180_CD 977_CD Between_IN three_CD and_CC four_CD years_NNS 318_CD 180_CD 46_CD Between_IN four_CD and_CC five_CD years_NNS 271_CD 180_CD After_IN five_CD years_NNS 6,188_CD 2,425_CD 9,195_CD 8,123_CD 1,923_CD Obligations_NNS under_IN finance_NN leases_NNS are_VBP repayable_JJ as_IN follows_VBZ :_: Between_IN one_CD and_CC two_CD years_NNS 91_CD 97_CD Between_IN two_CD and_CC three_CD years_NNS 96_CD 55_CD Between_IN three_CD and_CC four_CD years_NNS 19 83 206 235_CD At_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD a_DT property_NN mortgage_NN facility_NN with_IN the_DT Basellandschaftliche_NNP Kantonalbank_NNP of_IN 7.5_CD million_CD CHF_NNP 16.7_CD million_CD of_IN which_WDT 0.3_CD million_CD CHF_NNP 0.6_CD million_CD is_VBZ shown_VBN within_IN current_JJ liabilities_NNS ._.
The_DT mortgage_NN is_VBZ in_IN two_CD tranches_NNS ,_, both_DT secured_VBN by_IN the_DT assets_NNS of_IN Jago_NNP and_CC guaranteed_VBN by_IN SkyePharma_NNP PLC._NNP ._.
The_DT first_JJ tranche_NN of_IN 3.2_CD million_CD CHF_NNP 7.0_CD million_CD bears_NNS interest_NN at_IN 3.75_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 21_CD years_NNS semi-annually_RB ._.
The_DT second_JJ tranche_NN of_IN 4.3_CD million_CD CHF_NNP 9.7_CD million_CD bears_NNS interest_NN at_IN 3.0_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS over_IN 51_CD years_NNS ._.
At_IN 31_CD December_NNP 2003_CD ,_, the_DT Group_NNP had_VBD a_DT loan_NN with_IN GE_NNP Capital_NNP Corp_NNP of_IN 2.7_CD million_CD $_$ 5_CD million_CD of_IN which_WDT 0.8_CD million_CD is_VBZ shown_VBN within_IN current_JJ liabilities_NNS ._.
The_DT loan_NN is_VBZ secured_VBN by_IN certain_JJ assets_NNS of_IN SkyePharma_NNP Inc_NNP ,_, SkyePharma_NNP US_NNP Inc_NNP and_CC SkyePharma_NNP PLC._NNP ._.
The_DT loan_NN bears_VBZ interest_NN at_IN 8_CD %_NN and_CC is_VBZ repayable_JJ by_IN instalments_NNS from_IN 2004_CD until_IN between_IN 2005_CD and_CC 2007_CD ._.
In_IN 2000_CD ,_, the_DT Company_NN issued_VBN 59.4_CD million_CD 6_CD %_NN Convertible_JJ Bonds_NNS the_DT Bonds_NNS due_JJ 2005_CD ._.
The_DT Bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 83_CD pence_NN at_IN any_DT time_NN up_RP to_TO 19_CD June_NNP 2005_CD ._.
Unless_IN previously_RB redeemed_VBN or_CC converted_VBN ,_, the_DT Bonds_NNS will_MD be_VB redeemed_VBN by_IN the_DT Company_NN at_IN their_PRP$ principal_JJ amount_NN on_IN 19_CD June_NNP 2005_CD ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 70_CD 71_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 18_CD Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS National_NNP Restructuring_NNP Pension_NNP Insurance_NNP Total_NNP Group_NNP 000 000 000 000_CD At_IN 1_CD January_NNP 2003 201 201_CD Exchange_NNP adjustments_NNS 23_CD 30_CD 7_CD Charge_NNP in_IN the_DT year_NN 2,673_CD 54_CD 7_CD 2,734_CD Utilised_NNP 821_CD 821_CD At_IN 31_CD December_NNP 2003_CD 1,829_CD 285_CD 7_CD 2,121_CD Restructuring_NN provision_NN The_DT restructuring_NN provision_NN relates_VBZ to_TO the_DT reorganisation_NN of_IN research_NN and_CC development_NN operations_NNS and_CC other_JJ business_NN functions_NNS involving_VBG reductions_NNS in_IN staff_NN at_IN most_JJS sites_NNS note_VBP 4_CD :_: Exceptional_JJ items_NNS ._.
The_DT remaining_VBG provision_NN of_IN approximately_RB 1.8_CD million_CD will_MD be_VB utilised_VBN in_IN 2004_CD ._.
Pension_NNP provision_NN The_DT pension_NN provision_NN relates_VBZ to_TO the_DT retirement_NN commitments_NNS under_IN a_DT defined_VBN benefit_NN scheme_NN for_IN SkyePharma_NNP Production_NNP SAS_NNP employees_NNS note_VBP 26_CD :_: Pension_NNP Arrangements_NNP ._.
National_NNP Insurance_NNP provision_NN A_DT balance_NN sheet_NN provision_NN of_IN 7,000_CD 31_CD December_NNP 2002_CD :_: Nil_NNP has_VBZ been_VBN recognized_VBN in_IN accordance_NN with_IN UITF25_NNP :_: National_NNP Insurance_NNP contributions_NNS on_IN share_NN option_NN gains_NNS ._.
19_CD Deferred_JJ taxation_NN Group_NNP full_JJ potential_JJ Company_NN full_JJ potential_JJ 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000 000_CD 000_CD Accelerated_VBN capital_NN allowances_NNS 8,655_CD 4,848_CD 19_CD 42_CD Other_JJ timing_NN differences_NNS 8,485_CD 6,866_CD 18_CD 17_CD UK_NNP tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 2,063_CD 1,288_CD 2,063_CD 1,288_CD Overseas_JJ tax_NN benefits_NNS from_IN losses_NNS carried_VBD forward_RB 36,607_CD 29,731_CD Potential_JJ deferred_JJ tax_NN asset_NN 55,810_CD 42,733_CD 2,100_CD 1,347_CD No_DT deferred_VBN tax_NN asset_NN is_VBZ recognized_VBN ,_, given_VBN the_DT uncertainty_NN of_IN the_DT recoverability_NN of_IN the_DT Groups_NNS tax_NN losses_NNS carried_VBD forward_RB ._.
20_CD Contingent_JJ liabilities_NNS and_CC guarantees_NNS At_IN 31_CD December_NNP 2003_CD the_DT Company_NN had_VBD provided_VBN guarantees_NNS on_IN various_JJ bank_NN borrowings_NNS of_IN its_PRP$ subsidiaries_NNS as_IN set_VBN out_RP in_IN note_NN 16_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ within_IN one_CD year_NN and_CC note_NN 17_CD :_: Creditors_NNS :_: amounts_NNS falling_VBG due_JJ after_IN more_JJR than_IN one_CD year_NN ._.
In_IN common_JJ with_IN most_JJS business_NN enterprises_NNS ,_, Group_NNP companies_NNS are_VBP subject_JJ to_TO a_DT number_NN of_IN claims_NNS from_IN third_JJ parties_NNS ,_, the_DT outcome_NN of_IN which_WDT can_MD not_RB at_IN present_JJ be_VB determined_VBN but_CC which_WDT are_VBP not_RB considered_VBN to_TO be_VB material_NN in_IN the_DT context_NN of_IN these_DT Financial_NNP Statements_NNP ._.
Provision_NNP has_VBZ been_VBN made_VBN in_IN these_DT accounts_NNS for_IN any_DT liabilities_NNS which_WDT are_VBP expected_VBN to_TO materialise_VB from_IN such_JJ claims_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 21_CD Commitments_NNP Group_NNP Group_NNP Company_NNP Company_NNP 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000 000_CD 000_CD Capital_NN commitments_NNS Contracted_VBN for_IN but_CC not_RB provided_VBN in_IN the_DT accounts_NNS 197_CD Commitments_NNS under_IN operating_VBG leases_NNS to_TO pay_VB rentals_NNS for_IN the_DT next_JJ year_NN Operating_VBG leases_NNS on_IN land_NN and_CC buildings_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 50_CD 28_CD In_IN two_CD to_TO five_CD years_NNS 583 707 583 566_CD In_IN five_CD years_NNS or_CC more_JJR 2,832_CD 1,816_CD 3,415_CD 2,573_CD 583_CD 594_CD Other_JJ operating_NN leases_NNS which_WDT expire_VBP :_: In_IN one_CD year_NN or_CC less_JJR 7_CD 18_CD 7_CD 5_CD In_IN two_CD to_TO five_CD years_NNS 38_CD 53_CD 12_CD 11_CD 45_CD 71_CD 19_CD 16_CD In_IN addition_NN the_DT Group_NNP has_VBZ committed_VBN to_TO undertake_VB certain_JJ clinical_JJ trials_NNS on_IN behalf_NN of_IN its_PRP$ partners_NNS under_IN development_NN and_CC licensing_NN agreements_NNS ._.
The_DT Group_NNP is_VBZ committed_VBN to_TO make_VB certain_JJ payments_NNS to_TO third_JJ parties_NNS contingent_JJ upon_IN future_JJ events_NNS such_JJ as_IN the_DT approval_NN and_CC launch_NN of_IN products_NNS ._.
22_CD Share_NN capital_NN Equity_NN share_NN capital_NN 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD Number_NNP of_IN shares_NNS Number_NNP of_IN shares_NNS 000_CD 000_CD Authorised_NNP Ordinary_NNP Shares_NNP of_IN 10p_CD each_DT 1,114,000,000_CD 1,114,000,000_CD 111,400_CD 111,400_CD Ordinary_NNP shares_NNS of_IN Nominal_NNP 10p_CD each_DT Value_NN Number_NN 000_CD Issued_VBN ,_, allotted_VBN and_CC fully_RB paid_VBN At_IN 1_CD January_NNP 2002_CD 560,023,339_CD 56,002_CD Exercise_NN of_IN B_NNP Warrants_NNPS 2,051,607_CD 205_CD Exercise_NN of_IN share_NN options_NNS 1,323,853_CD 133_CD Issue_NN of_IN shares_NNS in_IN respect_NN of_IN RTP_NNP Pharma_NNP Inc._NNP 8,059,268_CD 806_CD Issue_NN of_IN shares_NNS to_TO Kowa_NNP Company_NNP Limited_NNP 30,000,000_CD 3,000_CD Conversion_NNP of_IN Deferred_NNP A_NNP Shares_NNP 12,000,000_CD 1,200_CD At_IN 31_CD December_NNP 2002_CD 613,458,067_CD 61,346_CD Exercise_NN of_IN share_NN options_NNS 1,521,662_CD 152_CD Issue_NN of_IN shares_NNS in_IN respect_NN of_IN RTP_NNP Pharma_NNP Inc._NNP 3,690,211_CD 369_CD At_IN 31_CD December_NNP 2003_CD 618,669,940_CD 61,867_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 72_CD 73_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 22_CD Share_NN capital_NN continued_VBD As_IN part_NN of_IN the_DT 2001_CD RTP_NNP acquisition_NN ,_, deferred_VBN consideration_NN of_IN 3,690,211_CD SkyePharma_NNP Ordinary_NNP Shares_NNP were_VBD issued_VBN to_TO the_DT former_JJ RTP_NNP shareholders_NNS during_IN the_DT year_NN ._.
The_DT cash_NN consideration_NN received_VBN on_IN the_DT issue_NN of_IN Ordinary_NNP Shares_NNP during_IN the_DT year_NN amounted_VBD to_TO 1,437,000_CD 2002_CD :_: 26,168,000_CD ._.
Non-equity_JJ share_NN capital_NN Deferred_VBN B_NNP Shares_NNP of_IN Nominal_NNP 10p_CD each_DT Value_NN Number_NN 000_CD Authorised_NNP and_CC issued_VBN At_IN 1_CD January_NNP 2003_CD and_CC 31_CD December_NNP 2003_CD 12,000,000_CD 1,200_CD 12_CD million_CD Deferred_NNP A_NNP and_CC 12_CD million_CD Deferred_NNP B_NNP Shares_NNP were_VBD issued_VBN to_TO Dr_NNP Gonella_NNP ,_, the_DT vendor_NN of_IN Jago_NNP ,_, on_IN 20_CD July_NNP 2000_CD under_IN the_DT Settlement_NNP Agreement_NN that_WDT established_VBD the_DT full_JJ and_CC final_JJ settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
The_DT holders_NNS of_IN Deferred_NNP A_NNP and_CC B_NNP Shares_NNP have_VBP no_DT rights_NNS to_TO participate_VB in_IN the_DT profits_NNS of_IN the_DT Company_NN ,_, no_DT voting_NN rights_NNS and_CC on_IN a_DT winding_VBG up_RP or_CC other_JJ return_NN of_IN capital_NN only_RB receive_VB the_DT nominal_JJ value_NN of_IN their_PRP$ shares_NNS if_IN the_DT holders_NNS of_IN Ordinary_NNP Shares_NNP in_IN the_DT capital_NN of_IN the_DT Company_NN have_VBP received_VBN the_DT sum_NN of_IN 1_CD million_CD per_IN Ordinary_NNP Share_NNP and_CC ,_, as_IN such_JJ ,_, are_VBP classified_VBN as_IN non-equity_JJ shares_NNS ._.
Under_IN the_DT terms_NNS of_IN the_DT Settlement_NNP Agreement_NNP ,_, following_VBG the_DT US_NNP launch_NN and_CC first_JJ commercial_JJ sale_NN of_IN Paxil_NNP CR_NNP by_IN GlaxoSmithKline_NNP in_IN 2002_CD ,_, the_DT 12_CD million_CD Deferred_NNP A_NNP Shares_NNP were_VBD automatically_RB converted_VBN into_IN 12_CD million_CD Ordinary_NNP Shares_NNP ._.
The_DT 12_CD million_CD Deferred_NNP B_NNP Shares_NNP automatically_RB convert_VBP to_TO 12_CD million_CD Ordinary_NNP Shares_NNP on_IN the_DT Companys_NNP receipt_NN of_IN a_DT royalty_NN statement_NN under_IN the_DT current_JJ Licence_NNP Agreement_NNP stating_VBG that_IN reported_VBD sales_NNS of_IN Paroxetine_NNP Paxil_NNP in_IN combination_NN with_IN the_DT Geomatrix_NNP technology_NN have_VBP exceeded_VBN $_$ 1,000_CD million_CD during_IN any_DT calendar_NN period_NN prior_RB to_TO 1_CD January_NNP 2006_CD or_CC exceeded_VBD $_$ 337_CD million_CD between_IN 1_CD January_NNP 2006_CD and_CC 3_CD May_NNP 2006_CD ._.
In_IN the_DT event_NN that_IN this_DT condition_NN is_VBZ not_RB satisfied_JJ prior_RB to_TO 3_CD May_NNP 2006_CD ,_, the_DT Deferred_NNP B_NNP Shares_NNP will_MD not_RB be_VB converted_VBN and_CC will_MD be_VB canceled_VBN ._.
The_DT vendor_NN will_MD not_RB be_VB entitled_VBN to_TO any_DT other_JJ nor_CC additional_JJ compensation_NN ._.
The_DT Deferred_JJ A_DT and_CC B_NNP Shares_NNP were_VBD issued_VBN on_IN 20_CD July_NNP 2000_CD when_WRB the_DT price_NN of_IN an_DT Ordinary_NNP Share_NN was_VBD 94.25_CD pence_NN ._.
The_DT difference_NN between_IN the_DT nominal_JJ value_NN of_IN the_DT Deferred_NNP B_NNP Shares_NNP and_CC their_PRP$ fair_JJ value_NN ,_, taken_VBN to_TO be_VB 94.25_CD pence_NNS ,_, at_IN issue_NN has_VBZ been_VBN recorded_VBN as_IN non-equity_JJ share_NN premium_NN ._.
Warrants_NNS The_DT Company_NN has_VBZ the_DT following_JJ warrants_NNS outstanding_JJ :_: a_DT D_NNP and_CC E_NNP warrants_NNS The_DT D_NNP and_CC E_NNP Warrants_NNS were_VBD issued_VBN in_IN March_NNP 2002_CD as_IN part_NN of_IN the_DT consideration_NN for_IN the_DT agreement_NN with_IN Paul_NNP Capital_NNP to_TO fund_VB new_JJ product_NN development_NN ._.
The_DT D_NNP and_CC E_NNP Warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 5_CD million_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN to_TO 31_CD December_NNP 2008_CD at_IN an_DT exercise_NN price_NN of_IN 73.75_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 0.3_CD million_CD has_VBZ been_VBN attributed_VBN to_TO the_DT D_NNP and_CC E_NNP Warrants_NNS which_WDT has_VBZ been_VBN recorded_VBN within_IN Other_JJ Reserves_NNS ._.
b_NN F_NN warrants_NNS The_DT F_NN Warrants_NNS were_VBD issued_VBN in_IN December_NNP 2003_CD as_IN part_NN of_IN the_DT 2.7_CD million_CD $_$ 5_CD million_CD loan_NN with_IN GE_NNP Capital_NNP Corp._NNP ._.
The_DT F_NN Warrants_NNS entitle_VBP the_DT holders_NNS to_TO subscribe_VB for_IN a_DT total_NN of_IN 300,000_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN until_IN the_DT repayment_NN date_NN of_IN the_DT loan_NN at_IN an_DT exercise_NN price_NN of_IN 1.20_CD per_IN Ordinary_NNP Share_NNP ._.
A_DT value_NN of_IN 39,000_CD has_VBZ been_VBN attributed_VBN to_TO the_DT F_NN Warrants_NNS which_WDT has_VBZ been_VBN recorded_VBN within_IN Other_JJ Reserves_NNS ._.
c_NN Other_JJ warrants_NNS Warrants_NNS were_VBD issued_VBN in_IN December_NNP 1999_CD as_IN part_NN of_IN the_DT acquisition_NN of_IN DepoTech_NNP and_CC entitle_VB the_DT holders_NNS to_TO subscribe_VB for_IN 291,777_CD Ordinary_NNP Shares_NNP at_IN any_DT time_NN during_IN the_DT period_NN beginning_VBG 31_CD December_NNP 1999_CD and_CC ending_VBG on_IN 25_CD February_NNP 2005_CD at_IN an_DT exercise_NN price_NN of_IN $_$ 1.453_CD 90.25_CD pence_NN per_IN Ordinary_NNP Share_NNP ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 22_CD Share_NN capital_NN continued_VBD Share_NN options_NNS The_DT Company_NN encourages_VBZ employee_NN participation_NN in_IN its_PRP$ shares_NNS through_IN ownership_NN and_CC continues_VBZ to_TO operate_VB various_JJ Share_NN Option_NN Schemes_NNS and_CC the_DT Unapproved_NNP Share_NN Option_NN Scheme_NN ._.
Under_IN the_DT terms_NNS of_IN these_DT Schemes_NNS the_DT Board_NNP may_MD offer_VB options_NNS to_TO purchase_VB Ordinary_NNP Shares_NNP in_IN the_DT Company_NN to_TO employees_NNS ,_, including_VBG Directors_NNS ,_, at_IN a_DT price_NN not_RB less_JJR than_IN the_DT higher_JJR of_IN the_DT nominal_JJ value_NN and_CC the_DT market_NN value_NN of_IN the_DT shares_NNS on_IN the_DT date_NN of_IN grant_NN ._.
Options_NNS granted_VBN to_TO UK_NNP and_CC European_JJ employees_NNS are_VBP only_RB exercisable_JJ between_IN the_DT third_JJ and_CC tenth_NN anniversary_NN of_IN the_DT date_NN of_IN grant_NN ,_, and_CC are_VBP subject_JJ to_TO the_DT Companys_NNP Code_NNP of_IN Conduct_NNP for_IN dealing_VBG in_IN Shares_NNP ,_, and_CC the_DT Model_NNP Code_NNP ._.
Options_NNS granted_VBN to_TO US_NNP employees_NNS prior_RB to_TO 2001_CD vest_NN at_IN 25_CD %_NN per_IN annum_NN from_IN the_DT date_NN of_IN grant_NN and_CC there_EX were_VBD no_DT performance_NN criteria_NNS ._.
UK_NNP and_CC European_JJ options_NNS granted_VBN prior_RB to_TO 2001_CD may_MD only_RB be_VB exercised_VBN if_IN the_DT growth_NN in_IN the_DT Companys_NNP share_NN price_NN over_IN a_DT consecutive_JJ three-year_JJ period_NN exceeds_VBZ the_DT growth_NN over_IN the_DT same_JJ period_NN in_IN the_DT FT-SE_NNP All_NNP Share_NNP Index_NNP ._.
This_DT criteria_NNS was_VBD satisfied_VBN for_IN the_DT first_JJ time_NN in_IN March_NNP 2000_CD ._.
Employees_NNS with_IN options_NNS that_WDT are_VBP within_IN their_PRP$ exercise_NN period_NN are_VBP now_RB able_JJ to_TO exercise_VB those_DT options_NNS within_IN any_DT one-year_JJ period_NN from_IN the_DT date_NN the_DT performance_NN condition_NN is_VBZ satisfied_VBN ._.
Super_NNP Options_NNPS are_VBP exercisable_JJ after_IN five_CD years_NNS and_CC are_VBP subject_JJ to_TO higher_JJR performance_NN conditions_NNS in_IN accordance_NN with_IN those_DT recommended_VBN by_IN the_DT Association_NNP of_IN British_NNP Insurers_NNP ._.
Following_VBG changes_NNS to_TO the_DT option_NN plans_VBZ approved_VBN at_IN the_DT Annual_JJ General_NNP Meeting_VBG in_IN June_NNP 2001_CD ,_, options_NNS granted_VBN to_TO Directors_NNS and_CC senior_JJ employees_NNS since_IN that_DT date_NN are_VBP subject_JJ to_TO performance_NN conditions_NNS linked_VBN to_TO the_DT total_JJ shareholder_NN return_NN of_IN a_DT comparator_NN group_NN of_IN companies_NNS ,_, and_CC are_VBP not_RB subject_JJ to_TO retesting_VBG ._.
Options_NNS granted_VBN to_TO other_JJ US_NNP employees_NNS continue_VBP to_TO vest_NN at_IN 25_CD %_NN per_IN annum_NN with_IN no_DT performance_NN criteria_NNS ,_, and_CC other_JJ European_JJ employees_NNS who_WP are_VBP not_RB Directors_NNS or_CC senior_JJ employees_NNS can_MD exercise_VB their_PRP$ options_NNS after_IN three_CD years_NNS and_CC are_VBP not_RB subject_JJ to_TO performance_NN conditions_NNS ._.
The_DT Groups_NNS plans_NNS are_VBP further_JJ detailed_VBN in_IN the_DT Remuneration_NNP Report_NNP ._.
The_DT market_NN value_NN of_IN Ordinary_NNP Shares_NNP during_IN 2003_CD ranged_VBD from_IN the_DT lowest_JJS closing_NN mid-price_NN of_IN 41.5_CD pence_NN to_TO the_DT highest_JJS closing_NN mid-price_NN of_IN 79.25_CD pence_NN per_IN share_NN ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 74_CD 75_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 22_CD Share_NN capital_NN continued_VBD At_IN 31_CD December_NNP 2003_CD the_DT following_VBG Ordinary_NNP Shares_NNP were_VBD under_IN option_NN to_TO employees_NNS or_CC former_JJ employees_NNS of_IN the_DT Group_NNP :_: Option_NN price_NN for_IN each_DT Number_NN of_IN options_NNS over_IN Expiry_NNP date_NN Ordinary_NNP Share_NN of_IN 10p_CD Ordinary_NNP Shares_NNP of_IN 10p_CD 29_CD April_NNP 2006_CD 75.0_CD p_NN 1,427,676_CD 28_CD May_NNP 2006_CD 92.0_CD p_NN 417,255_CD 6_CD December_NNP 2006_CD 81.0_CD p_NN 1,234,568_CD 7_CD April_NNP 2007_CD 66.5_CD p_NN 631,318_CD 28_CD January_NNP 2008_CD 51.0_CD p_NN 124,073_CD 31_CD March_NNP 2008_CD 93.0_CD p_NN 796,362_CD 5_CD October_NNP 2008_CD 44.8_CD p_NN 627,770_CD 19_CD April_NNP 2009_CD 69.5_CD p_NN 3,207,840_CD 25_CD May_NNP 2009_CD 56.7_CD p_NN 7,797,226_CD 7_CD September_NNP 2009_CD 56.9_CD p_NN 191,066_CD 6_CD June_NNP 2010_CD 91.3_CD p_NN 848,480_CD 3_CD November_NNP 2010_CD 81.7_CD p_NN 1,595,526_CD 12_CD June_NNP 2011_CD 80.6_CD p_NN 6,092,141_CD 31_CD October_NNP 2011_CD 55.6_CD p_NN 1,194,924_CD 24_CD December_NNP 2011_CD 55.1_CD p_NN 552,514_CD 12_CD April_NNP 2012_CD 72.3_CD p_NN 8,359,909_CD 24_CD May_NNP 2012_CD 78.6_CD p_NN 515,653_CD 25_CD September_NNP 2012_CD 51.7_CD p_NN 1,226,189_CD 7_CD April_NNP 2013_CD 46.5_CD p_NN 15,142,062_CD 26_CD September_NNP 2013_CD 62.0_CD p_NN 362,666_CD 52,345,218_CD 23_CD Shares_NNP and_CC warrants_NNS to_TO be_VB issued_VBN Group_NNP and_CC Company_NNP 000_CD At_IN 1_CD January_NNP 2003_CD and_CC 31_CD December_NNP 2003_CD a_DT Krypton_NNP The_NNP deferred_JJ consideration_NN on_IN the_DT acquisition_NN of_IN Krypton_NNP provides_VBZ that_IN a_DT maximum_NN of_IN 37.5_CD million_CD Ordinary_NNP Shares_NNP would_MD be_VB issued_VBN contingent_NN on_IN a_DT change_NN in_IN control_NN of_IN the_DT Company_NN at_IN a_DT share_NN price_NN of_IN not_RB less_JJR than_IN 80_CD pence_NNS compounded_VBN at_IN an_DT annual_JJ rate_NN of_IN 10_CD %_NN 1.71_CD as_RB at_IN 31_CD December_NNP 2003_CD ,_, or_CC satisfaction_NN of_IN various_JJ conditions_NNS and_CC hurdles_NNS which_WDT lapsed_VBD on_IN 31_CD December_NNP 2003_CD ._.
No_DT provision_NN for_IN deferred_JJ consideration_NN has_VBZ been_VBN recognized_VBN as_IN at_IN 31_CD December_NNP 2003_CD ._.
b_NN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP In_IN March_NNP 2002_CD the_DT Group_NNP announced_VBD a_DT second_JJ transaction_NN with_IN Paul_NNP Capital_NNP Royalty_NNP Acquisition_NNP Fund_NNP under_IN which_WDT SkyePharma_NNP will_MD issue_VB Ordinary_NNP Shares_NNP up_IN to_TO a_DT value_NN of_IN $_$ 7.5_CD million_CD if_IN royalties_NNS and_CC milestones_NNS received_VBN by_IN SkyePharma_NNP in_IN respect_NN of_IN those_DT products_NNS included_VBD in_IN the_DT transaction_NN are_VBP not_RB in_IN excess_NN of_IN minimum_JJ annual_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ._.
During_IN 2003_CD the_DT royalties_NNS received_VBN by_IN SkyePharma_NNP were_VBD substantially_RB in_IN excess_NN of_IN the_DT minimum_JJ payments_NNS required_VBN to_TO be_VB made_VBN to_TO Paul_NNP Capital_NNP ,_, consequently_RB the_DT company_NN has_VBZ not_RB provided_VBN for_IN any_DT additional_JJ obligations_NNS under_IN this_DT provision_NN ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 24_CD Reserves_NNS Equity_NN Non-equity_NN Profit_NN and_CC share_NN share_NN Other_JJ loss_NN premium_NN premium_NN reserves_NNS account_VBP Group_NNP 000 000 000 000_CD At_IN 1_CD January_NNP 2003_CD 306,309_CD 10,110_CD 9,311_CD 264,006_CD Exchange_NNP adjustments_NNS 175_CD On_IN issue_NN of_IN shares_NNS and_CC warrants_NNS 2,191_CD 39_CD On_IN exercise_NN of_IN share_NN options_NNS 613_CD Loss_NN for_IN the_DT year_NN 43,223_CD Unrealised_NNP gain_NN on_IN contract_NN development_NN 2,029_CD At_IN 31_CD December_NNP 2003_CD 309,113_CD 10,110_CD 9,350_CD 305,375_CD Other_JJ reserves_NNS relate_VBP to_TO a_DT merger_NN reserve_NN on_IN acquisition_NN and_CC a_DT warrant_NN reserve_NN on_IN the_DT issue_NN of_IN the_DT D_NNP ,_, E_NNP and_CC F_NN Warrants_NNS ._.
As_IN at_IN 31_CD December_NNP 2003_CD the_DT cumulative_JJ amount_NN of_IN goodwill_NN eliminated_VBN against_IN reserves_NNS was_VBD 147,632,000_CD 2002_CD :_: 147,632,000_CD ._.
Equity_NN Non-equity_NN Profit_NN and_CC share_NN share_NN Other_JJ loss_NN premium_NN premium_NN reserves_NNS account_VBP Company_NN 000 000 000 000_CD At_IN 1_CD January_NNP 2003_CD 306,309_CD 10,110_CD 9,311_CD 16,348_CD On_IN issue_NN of_IN shares_NNS and_CC warrants_NNS 2,191_CD 39_CD On_IN exercise_NN of_IN share_NN options_NNS 613_CD Loss_NN for_IN the_DT year_NN 821_CD At_IN 31_CD December_NNP 2003_CD 309,113_CD 10,110_CD 9,350_CD 17,169_CD As_IN permitted_VBN by_IN Section_NN 230_CD of_IN the_DT Companies_NNS Act_NNP 1985_CD ,_, the_DT Profit_NN and_CC Loss_NN Account_NNP of_IN the_DT Company_NN is_VBZ not_RB presented_VBN ._.
The_DT loss_NN attributable_JJ to_TO shareholders_NNS dealt_VBN with_IN in_IN the_DT accounts_NNS of_IN the_DT Company_NN is_VBZ 821,000_CD 2002_CD :_: 146,000_CD profit_NN ._.
25_CD Financial_NNP instruments_NNS The_DT Group_NNP holds_VBZ financial_JJ instruments_NNS to_TO finance_VB its_PRP$ operations_NNS and_CC to_TO manage_VB the_DT currency_NN risk_NN that_WDT arises_VBZ from_IN these_DT operations_NNS ._.
The_DT Group_NNP finances_VBZ its_PRP$ operations_NNS through_IN a_DT combination_NN of_IN equity_NN ,_, convertible_JJ bonds_NNS ,_, bank_NN loans_NNS and_CC other_JJ borrowings_NNS ._.
The_DT main_JJ risks_NNS arising_VBG from_IN the_DT groups_NNS financial_JJ instruments_NNS are_VBP liquidity_NN risk_NN ,_, foreign_JJ currency_NN risk_NN ,_, interest_NN rate_NN risk_NN and_CC credit_NN risk_NN ._.
Liquidity_NN risk_NN The_DT Groups_NNS policy_NN is_VBZ to_TO maintain_VB continuity_NN of_IN funding_VBG through_IN a_DT mixture_NN of_IN long-term_JJ debt_NN and_CC bank_NN loans_NNS ,_, raised_VBD to_TO cover_VB specific_JJ projects_NNS ,_, and_CC through_IN the_DT issue_NN of_IN shares_NNS to_TO collaborative_JJ partners_NNS ,_, where_WRB necessary_JJ ,_, to_TO finance_VB development_NN contracts_NNS ._.
Short-term_JJ flexibility_NN is_VBZ provided_VBN through_IN the_DT use_NN of_IN overdrafts_NNS ._.
The_DT maturity_NN profile_NN of_IN the_DT Groups_NNS debt_NN is_VBZ set_VBN out_RP below_IN at_IN note_NN c._NN Foreign_JJ currency_NN risk_NN All_DT of_IN the_DT Groups_NNS operations_NNS are_VBP based_VBN overseas_RB in_IN Continental_NNP Europe_NNP and_CC North_NNP America_NNP giving_VBG rise_NN to_TO exposures_NNS to_TO changes_NNS in_IN foreign_JJ exchange_NN rates_NNS notably_RB the_DT Swiss_JJ Franc_NN ,_, Euro_NNP ,_, Swedish_NNP Krona_NNP ,_, US_NNP Dollar_NNP and_CC Canadian_NNP Dollar_NNP ._.
To_TO minimize_VB the_DT impact_NN of_IN any_DT fluctuations_NNS ,_, the_DT Groups_NNS policy_NN has_VBZ historically_RB been_VBN to_TO maintain_VB natural_JJ hedges_NNS by_IN relating_VBG the_DT structure_NN of_IN borrowings_NNS to_TO the_DT trading_NN cash_NN flows_VBZ that_IN generate_VB them_PRP ._.
Where_WRB subsidiaries_NNS are_VBP funded_VBN centrally_RB ,_, this_DT is_VBZ achieved_VBN by_IN the_DT use_NN of_IN long-term_JJ loans_NNS ,_, the_DT exchange_NN differences_NNS on_IN which_WDT are_VBP taken_VBN to_TO reserves_NNS ._.
Where_WRB it_PRP has_VBZ not_RB been_VBN possible_JJ to_TO use_VB natural_JJ hedges_NNS ,_, currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS are_VBP used_VBN ._.
The_DT Group_NNP has_VBZ used_VBN these_DT financial_JJ instruments_NNS during_IN the_DT year_NN to_TO minimize_VB the_DT currency_NN exposure_NN on_IN operational_JJ transactions_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 76_CD 77_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 25_CD Financial_NNP instruments_NNS continued_VBD Interest_NN rate_NN risk_NN The_DT Group_NNP borrows_VBZ at_IN fixed_VBN and_CC floating_VBG rates_NNS of_IN interest_NN as_IN deemed_VBN appropriate_JJ for_IN its_PRP$ circumstances_NNS ._.
Where_WRB necessary_JJ the_DT Group_NNP uses_VBZ several_JJ interest_NN rate_NN swaps_NNS to_TO achieve_VB the_DT desired_VBN interest_NN rate_NN profile_NN ._.
During_IN the_DT year_NN the_DT Group_NNP had_VBD several_JJ cancellable_JJ ,_, floating_VBG rate_NN ,_, interest_NN rate_NN swaps_NNS on_IN 30_CD million_CD of_IN the_DT 6_CD %_NN convertible_JJ bond_NN liability_NN ._.
The_DT interest_NN rate_NN profile_NN of_IN the_DT Groups_NNS financial_JJ assets_NNS and_CC liabilities_NNS is_VBZ set_VBN out_RP in_IN notes_NNS a_DT and_CC b_NN respectively_RB ._.
Credit_NNP risk_NN The_NNP Group_NNP is_VBZ exposed_VBN to_TO credit_NN related_VBN losses_NNS in_IN the_DT event_NN of_IN non-performance_JJ by_IN third_JJ parties_NNS to_TO financial_JJ instruments_NNS ._.
The_DT Group_NNP does_VBZ not_RB expect_VB any_DT third_JJ parties_NNS to_TO fail_VB to_TO meet_VB their_PRP$ obligations_NNS given_VBN the_DT policy_NN of_IN selecting_VBG only_RB parties_NNS with_IN high_JJ credit_NN ratings_NNS and_CC minimizing_VBG its_PRP$ exposure_NN to_TO any_DT one_CD institution_NN ._.
In_IN the_DT numerical_JJ disclosures_NNS that_WDT follow_VBP ,_, short-term_JJ debtors_NNS and_CC creditors_NNS that_WDT arise_VBP directly_RB as_IN a_DT result_NN of_IN the_DT Groups_NNS operations_NNS are_VBP excluded_VBN from_IN all_DT disclosures_NNS with_IN the_DT exception_NN of_IN note_NN f_SYM on_IN currency_NN exposures_NNS ._.
a_DT Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ assets_NNS 31_CD December_NNP 2003_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Fixed_VBN rate_NN on_IN fixed_JJ time_NN for_IN rate_NN bearing_NN Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ financial_JJ assets_NNS assets_NNS is_VBZ fixed_VBN assets_NNS assets_NNS assets_NNS Currency_NNP 000_CD %_NN months_NNS 000 000 000_CD Sterling_NNP 7,981_CD 4.94_CD 15.2_CD 6,016_CD 2,129_CD 16,126_CD $_$ US_PRP 568_CD 12.00_CD 59.5_CD 7,335_CD 18,728_CD 26,631_CD Swiss_JJ francs_NNS 192_CD 2_CD 194_CD $_$ Canadian_JJ 821_CD 629_CD 1,450_CD Euro_NNP 1,170_CD 64_CD 1,234_CD Swedish_NNP Krona_NNP 610_CD 610_CD 8,549_CD 5.41_CD 18.1_CD 16,144_CD 21,552_CD 46,245_CD Total_JJ financial_JJ assets_NNS comprise_VBP fixed_VBN asset_NN investments_NNS of_IN 22.0_CD million_CD 2002_CD :_: 18.9_CD million_CD ,_, current_JJ asset_NN investments_NNS of_IN 1.0_CD million_CD 2002_CD :_: 2.0_CD million_CD and_CC cash_NN and_CC short-term_JJ bank_NN deposits_NNS of_IN 23.2_CD million_CD 2002_CD :_: 28.1_CD million_CD ._.
Floating_VBG rate_NN financial_JJ assets_NNS bear_VBP interest_NN at_IN rates_NNS based_VBN upon_IN the_DT floating_VBG base_NN rate_NN in_IN the_DT country_NN in_IN which_WDT the_DT funds_NNS are_VBP held_VBN ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 25_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2002_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Fixed_VBN rate_NN on_IN fixed_JJ time_NN for_IN rate_NN bearing_NN Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ financial_JJ assets_NNS assets_NNS is_VBZ fixed_VBN assets_NNS assets_NNS assets_NNS Currency_NNP 000_CD %_NN months_NNS 000 000 000_CD Sterling_NNP 1,961_CD 5.00_CD 54.0_CD 18,680_CD 36_CD 20,677_CD $_$ US_PRP 4,292_CD 16,663_CD 20,955_CD Swiss_JJ francs_NNS 1,870_CD 1,870_CD $_$ Canadian_JJ 2,026_CD 2,228_CD 4,254_CD Euro_NNP 617_CD 617_CD Swedish_NNP Krona_NNP 523_CD 523_CD 1,961_CD 5.00_CD 54.0_CD 28,008_CD 18,927_CD 48,896_CD b_NN Interest_NN rate_NN and_CC currency_NN profile_NN of_IN financial_JJ liabilities_NNS The_DT interest_NN rate_NN risk_NN profile_NN of_IN the_DT Groups_NNS financial_JJ liabilities_NNS after_IN taking_VBG into_IN account_NN the_DT interest_NN rate_NN and_CC currency_NN swaps_NNS used_VBN to_TO manage_VB the_DT interest_NN and_CC currency_NN profile_NN was_VBD :_: 31_CD December_NNP 2003_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Weighted_NNP Fixed_NNP rate_NN on_IN fixed_JJ time_NN for_IN rate_NN bearing_NN average_JJ Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ time_NN to_TO financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS assets_NNS maturity_NN assets_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 29,400_CD 6.00_CD 17.5_CD 30,000_CD 11,310_CD 28.0_CD 70,710_CD $_$ US_PRP 2,701_CD 7.99_CD 35.7_CD 559_CD 3,070_CD 136.0_CD 6,330_CD Swiss_JJ francs_NNS 4,496_CD 3.66_CD 23.0_CD 5,940_CD 10,436_CD $_$ Canadian_JJ 389_CD 120.0_CD 389_CD Euro_NNP 285_CD 405.0_CD 285_CD Swedish_NNP Krona_NNP 235_CD 6.38_CD 26.2_CD 235_CD 36,832_CD 5.86_CD 19.6_CD 36,499_CD 15,054_CD 59.6_CD 88,385_CD Financial_NNP liabilities_NNS comprise_VBP total_JJ borrowings_NNS of_IN 13.6_CD million_CD 2002_CD :_: 10.0_CD million_CD ,_, convertible_JJ bonds_NNS of_IN 59.4_CD million_CD 2002_CD :_: 59.4_CD million_CD ,_, non-equity_JJ Deferred_NNP B_NNP Shares_NNP of_IN 11.3_CD million_CD 2002_CD :_: 11.3_CD million_CD ,_, other_JJ creditors_NNS of_IN 3.8_CD million_CD 2002_CD :_: 4.6_CD million_CD and_CC provisions_NNS of_IN 0.3_CD million_CD 2002_CD :_: 0.2_CD million_CD ._.
The_DT effect_NN of_IN the_DT Groups_NNS interest_NN rate_NN swap_NN is_VBZ to_TO classify_VB 30.0_CD million_CD of_IN the_DT convertible_JJ bond_NN in_IN the_DT above_JJ table_NN as_IN a_DT floating_VBG rate_NN financial_JJ liability_NN ._.
Total_JJ financial_JJ liabilities_NNS does_VBZ not_RB agree_VB to_TO the_DT total_NN of_IN the_DT balance_NN sheet_NN captions_NNS due_JJ to_TO the_DT presence_NN of_IN 609,000_CD 2002_CD :_: 1,023,000_CD of_IN unamortised_JJ issue_NN costs_NNS within_IN the_DT value_NN shown_VBN on_IN the_DT balance_NN sheet_NN for_IN convertible_JJ bonds_NNS ._.
All_DT floating_VBG rate_NN financial_JJ liabilities_NNS ,_, in_IN both_DT 2003_CD and_CC 2002_CD ,_, are_VBP interest_NN bearing_NN financial_JJ liabilities_NNS that_WDT bear_VBP interest_NN at_IN interest_NN rates_NNS based_VBN on_IN LIBOR_NNP ,_, prime_JJ and_CC other_JJ bank_NN based_VBN lending_NN rates_NNS in_IN the_DT country_NN in_IN which_WDT the_DT liability_NN arises_VBZ ,_, which_WDT are_VBP fixed_VBN for_IN periods_NNS of_IN up_RB to_TO 12_CD months_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 78_CD 79_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 25_CD Financial_NNP instruments_NNS continued_VBD 31_CD December_NNP 2002_CD Weighted_JJ average_JJ Weighted_NNP Noninterest_NNP rate_NN average_JJ Floating_VBG interest_NN Weighted_NNP Fixed_NNP rate_NN on_IN fixed_JJ time_NN for_IN rate_NN bearing_NN average_JJ Total_JJ financial_JJ financial_JJ which_WDT rate_NN financial_JJ financial_JJ time_NN to_TO financial_JJ liabilities_NNS liabilities_NNS is_VBZ fixed_VBN liabilities_NNS assets_NNS maturity_NN assets_NNS Currency_NNP 000_CD %_NN months_NNS 000_CD 000_CD months_NNS 000_CD Sterling_NNP 29,400_CD 6.00_CD 29.5_CD 30,000_CD 11,310_CD 40.0_CD 70,710_CD $_$ US_PRP 25_CD 5.25_CD 40.0_CD 621_CD 3,269_CD 144.0_CD 3,915_CD Swiss_JJ francs_NNS 4,560_CD 3.64_CD 13.5_CD 4,897_CD 9,457_CD Euro_NNP 863_CD 6.25_CD 11.0_CD 201_CD 417.0_CD 1,064_CD Swedish_NNP Krona_NNP 319_CD 7.25_CD 27.8_CD 319_CD 35,167_CD 5.71_CD 27.0_CD 35,518_CD 14,780_CD 68.1_CD 85,465_CD c_NN Maturity_NN of_IN financial_JJ liabilities_NNS 31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Within_IN one_CD year_NN 4,530_CD 2,927_CD Between_IN one_CD and_CC two_CD years_NNS 60,662_CD 5,256_CD Between_IN two_CD and_CC five_CD years_NNS 13,261_CD 71,587_CD Beyond_NNP five_CD years_NNS 9,932_CD 5,695_CD 88,385_CD 85,465_CD d_SYM Borrowing_VBG facilities_NNS As_IN at_IN 31_CD December_NNP 2003_CD the_DT Group_NNP had_VBD the_DT following_VBG undrawn_JJ committed_JJ borrowing_NN facilities_NNS available_JJ ._.
31_CD December_NNP 2003_CD 31_CD December_NNP 2002 000 000_CD Expiring_VBG within_IN one_CD year_NN 158_CD 1,646_CD e_SYM Fair_NNP values_VBZ The_DT comparison_NN of_IN fair_JJ and_CC book_NN values_NNS of_IN all_PDT the_DT Groups_NNS financial_JJ instruments_NNS as_IN at_IN 31_CD December_NNP 2003_CD is_VBZ set_VBN out_RP below_IN ._.
Market_NN value_NN ,_, or_CC Directors_NNS valuation_NN if_IN a_DT market_NN value_NN is_VBZ unavailable_JJ ,_, have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ value_NN of_IN fixed_VBN and_CC current_JJ asset_NN investments_NNS ._.
Market_NN values_NNS have_VBP been_VBN used_VBN to_TO determine_VB the_DT fair_JJ values_NNS of_IN all_DT swaps_NNS and_CC foreign_JJ currency_NN contracts_NNS ._.
The_DT fair_JJ value_NN of_IN the_DT non-equity_JJ Deferred_NNP B_NNP Shares_NNP has_VBZ been_VBN calculated_VBN by_IN reference_NN to_TO the_DT Ordinary_NNP Share_NN price_NN at_IN 31_CD December_NNP 2003_CD ,_, based_VBN upon_IN the_DT Directors_NNS opinion_NN that_WDT 12_CD million_CD Ordinary_NNP Shares_NNP will_MD be_VB issued_VBN in_IN settlement_NN of_IN the_DT deferred_JJ consideration_NN payable_JJ on_IN the_DT acquisition_NN of_IN Jago_NNP ._.
See_VB note_NN 22_CD :_: Share_NN capital_NN ,_, for_IN details_NNS of_IN the_DT contingencies_NNS that_WDT shall_MD determine_VB the_DT issuance_NN of_IN the_DT Ordinary_NNP Shares_NNP ._.
The_DT fair_JJ values_NNS of_IN all_DT other_JJ items_NNS have_VBP been_VBN calculated_VBN by_IN discounting_VBG future_JJ cash_NN flows_VBZ at_IN interest_NN rates_NNS prevailing_VBG at_IN 31_CD December_NNP 2003_CD ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 25_CD Financial_NNP instruments_NNS continued_VBD Book_NNP values_NNS Fair_NNP values_VBZ 31_CD December_NNP 2003 000 000_CD Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS Fixed_VBN asset_NN investments_NNS 22,024_CD 28,745_CD Current_JJ asset_NN investments_NNS 981_CD 981_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 3,052_CD 3,052_CD Short-term_JJ bank_NN deposits_NNS 20,188_CD 20,188_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long-term_JJ borrowings_NNS 4,530_CD 4,530_CD Long-term_JJ convertible_JJ debt_NN 59,400_CD 56,218_CD Other_JJ long-term_JJ debt_NN 13,145_CD 13,145_CD Non-equity_NN Deferred_VBN B_NNP Shares_NNP 11,310_CD 9,030_CD 42,140_CD 29,957_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Interest_NN rate_NN swaps_NNS 322_CD Canadian_JJ $_$ currency_NN options_NNS Euro_NNP currency_NN options_NNS 21_CD Swiss_JJ franc_NN currency_NN options_NNS 12_CD Swedish_JJ Krona_NNP currency_NN options_NNS 59_CD Forward_RB currency_NN contracts_NNS 18_CD 354_CD Book_NN values_NNS Fair_NNP values_VBZ 31_CD December_NNP 2002 000 000_CD Financial_NNP instruments_NNS held_VBD or_CC issued_VBD to_TO finance_VB the_DT Groups_NNS operations_NNS Fixed_VBN asset_NN investments_NNS 18,874_CD 17,287_CD Current_JJ asset_NN investments_NNS 1,961_CD 1,961_CD Cash_NN at_IN bank_NN and_CC in_IN hand_NN 7,394_CD 7,394_CD Short-term_JJ bank_NN deposits_NNS 20,667_CD 20,667_CD Short-term_JJ borrowings_NNS and_CC current_JJ portion_NN of_IN long-term_JJ borrowings_NNS 2,927_CD 2,927_CD Long-term_JJ convertible_JJ debt_NN 59,400_CD 53,863_CD Other_JJ long-term_JJ debt_NN 11,828_CD 11,707_CD Non-equity_NN Deferred_VBN B_NNP Shares_NNP 11,310_CD 4,980_CD 36,569_CD 26,168_CD Derivative_JJ financial_JJ instruments_NNS held_VBN to_TO manage_VB the_DT Groups_NNS currency_NN profile_NN Interest_NN rate_NN swaps_NNS 452_CD Euro_NNP currency_NN options_NNS 85_CD US$_$ currency_NN options_NNS 13_CD Forward_RB currency_NN contracts_NNS 146_CD 500_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 80_CD 81_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 25_CD Financial_NNP instruments_NNS continued_VBD f_SYM Currency_NNP exposures_NNS The_DT following_JJ analysis_NN shows_VBZ the_DT net_JJ monetary_JJ assets_NNS and_CC liabilities_NNS of_IN Group_NNP companies_NNS that_WDT are_VBP not_RB denominated_VBN in_IN their_PRP$ functional_JJ currency_NN and_CC therefore_RB give_VB rise_VB to_TO exchange_VB gains_NNS and_CC losses_NNS in_IN the_DT profit_NN and_CC loss_NN account_NN in_IN both_DT 2003_CD and_CC 2002_CD ._.
31_CD December_NNP 2003_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Swedish_JJ Swiss_JJ $_$ Krona_NNP Sterling_NNP $_$ US_PRP Euro_NNP francs_NNS Canadian_JJ Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000 000 000_CD Sterling_NNP 3,796_CD 847_CD 6_CD 4,649_CD $_$ US_PRP 3,579_CD 65_CD 3,644_CD Euro_NNP 245_CD 17_CD 2,622_CD 2,850_CD Swiss_JJ francs_NNS 5_CD 10,280_CD 2,419_CD 220_CD 12,474_CD $_$ Canadian_JJ 1,038_CD 1,391_CD 71_CD 424_CD Swedish_NNP Krona_NNP 2,568_CD 54_CD 2,622_CD 5_CD 5,416_CD 4,753_CD 491_CD 2,622_CD 6_CD 13,283_CD 31_CD December_NNP 2002_CD Net_JJ foreign_JJ currency_NN monetary_JJ assets_NNS liabilities_NNS Swiss_JJ $_$ Sterling_NNP $_$ US_PRP Euro_NNP francs_NNS Canadian_JJ Total_NNP Functional_NNP currency_NN of_IN Operating_VBG Company_NN 000 000 000 000_CD 000_CD 000_CD Sterling_NNP 2,232_CD 617_CD 1_CD 2,850_CD $_$ US_PRP 15,956_CD 9_CD 34_CD 15,999_CD Euro_NNP 2,025_CD 96_CD 2,225_CD 296_CD Swiss_JJ francs_NNS 928_CD 3,142_CD 528_CD 582_CD 1,104_CD $_$ Canadian_JJ 1,904_CD 400 130 550_CD 2,724_CD Swedish_NNP Krona_NNP 1,343_CD 1,343_CD 18,348_CD 5,870_CD 50_CD 2,775_CD 615_CD 10,368_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 25_CD Financial_NNP instruments_NNS continued_VBD g_JJ Hedging_NNP As_IN explained_VBN above_IN ,_, the_DT Groups_NNS policy_NN is_VBZ to_TO hedge_VB interest_NN rate_NN exposures_NNS through_IN the_DT use_NN of_IN interest_NN rate_NN swaps_NNS and_CC currency_NN exposures_NNS through_IN the_DT use_NN of_IN currency_NN options_NNS ,_, accrual_NN forward_RB options_NNS and_CC forward_JJ currency_NN contracts_NNS ._.
The_DT table_NN below_IN shows_NNS the_DT extent_NN to_TO which_WDT the_DT Group_NNP has_VBZ off-balance_JJ sheet_NN unrecognised_JJ and_CC on-balance_JJ sheet_NN deferred_VBN gains_NNS and_CC losses_NNS in_IN respect_NN of_IN hedges_NNS at_IN the_DT beginning_NN and_CC end_NN of_IN the_DT year_NN :_: 31_CD December_NNP 2003_CD Unrecognised_NNP Deferred_NNP Gains_NNS Losses_NNS Net_JJ total_NN Gains_NNS Losses_NNS Net_JJ total_NN 000 000 000 000_CD 000_CD 000_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2003_CD 598_CD 98_CD 500_CD Changes_NNS in_IN value_NN from_IN 1_CD January_NNP 2003_CD to_TO settlement_NN 6_CD 85_CD 91_CD Gains_NNS losses_NNS arising_VBG in_IN previous_JJ years_NNS recognized_VBN in_IN 2003_CD 152_CD 13_CD 139_CD Gains_NNS losses_NNS not_RB recognized_VBN in_IN 2003_CD arising_VBG before_IN 1_CD January_NNP 2003 452 452_CD Arising_VBG in_IN 2003_CD 59_CD 39_CD 98_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2003_CD 393_CD 39_CD 354_CD At_IN 31_CD December_NNP 2003_CD ,_, the_DT Company_NN had_VBD European_JJ style_NN accrual_NN forward_RB options_NNS to_TO purchase_VB 142,000_CD of_IN Sterling_NNP each_DT week_NN for_IN the_DT 4_CD weeks_NNS ending_VBG in_IN January_NNP 2004_CD ,_, 22,000_CD of_IN Euro_NNP each_DT week_NN for_IN the_DT 8_CD weeks_NNS ending_VBG in_IN February_NNP 2004_CD and_CC 123,000_CD of_IN Swiss_JJ Francs_NNS each_DT week_NN for_IN the_DT 36_CD weeks_NNS ending_VBG in_IN September_NNP 2004_CD ._.
In_IN addition_NN ,_, the_DT Company_NN had_VBD a_DT cylinder_NN structure_NN containing_VBG knock_VB ins_NNS to_TO purchase_VB 0.5_CD million_CD of_IN Swedish_JJ Krona_NNP each_DT month_NN for_IN the_DT 6_CD months_NNS ending_VBG in_IN June_NNP 2004_CD ._.
At_IN 31_CD December_NNP 2003_CD ,_, the_DT Company_NN had_VBD forward_JJ currency_NN contracts_NNS to_TO purchase_VB 4.6_CD million_CD of_IN Euro_NNP ,_, 2.3_CD million_CD of_IN US_NNP dollars_NNS ,_, 0.3_CD million_CD of_IN Swedish_JJ Krona_NNP and_CC to_TO sell_VB 0.3_CD million_CD of_IN Swiss_JJ Francs_NNS ._.
The_DT excess_NN of_IN fair_JJ values_NNS over_IN book_NN values_NNS for_IN currency_NN options_NNS shown_VBN in_IN note_NN 25_CD e_SYM represents_VBZ the_DT unrecognised_JJ hedging_NN gain_NN on_IN these_DT instruments_NNS as_IN at_IN 31_CD December_NNP 2003_CD ._.
The_DT actual_JJ gains_NNS or_CC losses_NNS arising_VBG on_IN these_DT currency_NN options_NNS will_MD be_VB dependent_JJ on_IN future_JJ exchange_NN rates_NNS and_CC will_MD be_VB recognized_VBN in_IN the_DT profit_NN and_CC loss_NN account_NN ,_, in_IN 2004_CD ,_, as_IN the_DT operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
Unrecognised_JJ gains_NNS at_IN 31_CD December_NNP 2003_CD include_VBP 0.3_CD million_CD in_IN relation_NN to_TO the_DT cancellable_JJ swap_NN agreement_NN ._.
This_DT is_VBZ based_VBN upon_IN the_DT swap_NN agreement_NN continuing_VBG for_IN the_DT life_NN of_IN the_DT convertible_JJ bond_NN ._.
The_DT Royal_NNP Bank_NNP of_IN Scotland_NNP last_JJ exercised_VBN its_PRP$ right_NN to_TO cancel_VB and_CC replace_VB the_DT swap_NN in_IN November_NNP 2002_CD ,_, and_CC it_PRP has_VBZ remained_VBN in_IN place_NN since_IN ._.
31_CD December_NNP 2002_CD Unrecognised_NNP Deferred_NNP Gains_NNS Losses_NNS Net_JJ total_NN Gains_NNS Losses_NNS Net_JJ total_NN 000 000 000 000_CD 000_CD 000_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 1_CD January_NNP 2002_CD 31_CD 31_CD 20_CD 20_CD Changes_NNS in_IN value_NN from_IN 1_CD January_NNP 2002_CD to_TO settlement_NN 262_CD 262_CD Gains_NNS losses_NNS arising_VBG in_IN 2001_CD recognized_VBN in_IN 2002 231 231_CD 20_CD 20_CD Gains_NNS losses_NNS not_RB recognized_VBN in_IN 2002_CD arising_VBG before_IN 1_CD January_NNP 2002_CD Arising_VBG in_IN 2002_CD 598_CD 98_CD 500_CD Gains_NNS losses_NNS on_IN hedges_NNS at_IN 31_CD December_NNP 2002_CD 598_CD 98_CD 500_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 82_CD 83_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 26_CD Pension_NNP arrangements_NNS The_DT Group_NNP operates_VBZ various_JJ defined_VBN contribution_NN plans_NNS for_IN its_PRP$ employees_NNS in_IN the_DT UK_NNP ,_, Switzerland_NNP ,_, US_NNP ,_, Sweden_NNP and_CC Canada_NNP ._.
The_DT Groups_NNS contributions_NNS to_TO these_DT plans_NNS are_VBP charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN the_DT period_NN to_TO which_WDT they_PRP relate_VBP ,_, and_CC the_DT assets_NNS are_VBP held_VBN in_IN separate_JJ trustee_NN administered_VBN funds_NNS ._.
The_DT Group_NNP operates_VBZ an_DT unfunded_JJ defined_VBN benefit_NN scheme_NN in_IN respect_NN of_IN its_PRP$ employees_NNS in_IN France_NNP based_VBN on_IN the_DT national_JJ collective_JJ agreement_NN of_IN the_DT pharmaceutical_JJ industry_NN ,_, and_CC a_DT provision_NN of_IN 285,000_CD is_VBZ included_VBN in_IN note_NN 18_CD :_: Provisions_NNS for_IN liabilities_NNS and_CC charges_NNS in_IN respect_NN of_IN these_DT obligations_NNS ._.
Under_IN the_DT transitional_JJ provisions_NNS of_IN FRS17_NNP :_: Retirement_NNP Benefits_NNPS certain_JJ disclosures_NNS for_IN the_DT defined_VBN benefit_NN scheme_NN in_IN France_NNP are_VBP required_VBN as_IN follows_VBZ :_: As_IN at_IN December_NNP 2003_CD a_DT valuation_NN was_VBD performed_VBN by_IN professionally_RB qualified_VBN actuaries_NNS ,_, Socit_NNP fide_NNP Prospective_JJ Actuariat_NNP et_NNP Conseil_NNP ,_, on_IN the_DT present_JJ value_NN of_IN the_DT accrued_VBN liabilities_NNS calculated_VBN under_IN the_DT projected_VBN unit_NN method_NN ._.
The_DT principal_JJ assumptions_NNS made_VBN by_IN the_DT actuaries_NNS were_VBD :_: 2003 2002 2001_CD %_NN per_IN %_NN per_IN %_NN per_IN annum_NN annum_NN annum_NN Inflation_NN rate_NN 1.75_CD 1.75_CD 2.0_CD Rate_NN of_IN increase_NN in_IN salaries_NNS 2.75_CD 2.75_CD 3.0_CD Discount_NNP rate_NN 5.25_CD 5.25_CD 5.5_CD Analysis_NN of_IN amounts_NNS charged_VBN to_TO the_DT profit_NN and_CC loss_NN account_NN in_IN respect_NN of_IN the_DT defined_VBN benefit_NN scheme_NN under_IN FRS_NNP 17 2003 2002 000_CD 000_CD Current_JJ service_NN cost_NN 18_CD 24_CD Past_JJ service_NN cost_NN Interest_NN on_IN pension_NN scheme_NN liabilities_NNS 22_CD 21_CD Total_JJ charge_NN to_TO the_DT profit_NN and_CC loss_NN account_NN 40_CD 45_CD Movement_NNP in_IN deficit_NN during_IN the_DT year_NN 2003 2002 000 000_CD Opening_NNP deficit_NN 382_CD 382_CD Exchange_NNP adjustment_NN 31_CD 25_CD Current_JJ service_NN charge_NN 40_CD 45_CD Benefit_NNP payments_NNS made_VBD 9_CD Unrecognised_JJ past_JJ service_NN cost_NN 183_CD Actuarial_NNP gain_NN recognized_VBD in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 33_CD 61_CD Closing_NN deficit_NN 603_CD 382_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 26_CD Pension_NNP arrangements_NNS continued_VBD Amounts_NNS recorded_VBN in_IN the_DT statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS under_IN FRS17_NNP 2003_CD 2002_CD Experience_NN gains_NNS arising_VBG on_IN scheme_NN liabilities_NNS 000_CD 24_CD 17_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 6_CD 4_CD Changes_NNS in_IN assumption_NN relating_VBG to_TO the_DT present_JJ value_NN of_IN scheme_NN liabilities_NNS 000_CD 9_CD 44_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 2_CD 12_CD Total_JJ actuarial_JJ gain_NN 000_CD 33_CD 61_CD Percentage_NN of_IN scheme_NN liabilities_NNS %_NN 16_CD 16_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS17_NNP 2003 2002 000 000_CD Profit_NN and_CC loss_NN reserve_NN per_IN balance_NN sheet_NN 305,375_CD 264,006_CD Pension_NN liability_NN under_IN FRS_NNP 17 603 382_CD Pension_NNP liability_NN under_IN SSAP_NNP 24_CD :_: Accounting_NNP for_IN pension_NN costs_NNS 285_CD 201_CD Profit_NN and_CC loss_NN reserve_NN under_IN FRS_NNP 17_CD 305,693_CD 264,187_CD Net_JJ assets_NNS under_IN FRS_NNP 17 2003 2002 000_CD 000_CD Net_JJ assets_NNS per_IN balance_NN sheet_NN 86,265_CD 124,270_CD Pension_NN liability_NN under_IN FRS_NNP 17 603 382_CD Pension_NNP liability_NN under_IN SSAP_NNP 24 285 201_CD Net_JJ assets_NNS under_IN FRS_NNP 17_CD 85,947_CD 124,089_CD 27_CD Related_VBN party_NN transactions_NNS At_IN the_DT end_NN of_IN December_NNP 1998_CD ,_, Ian_NNP Gowrie-Smith_NNP through_IN a_DT family-owned_JJ trust_NN acquired_VBD a_DT 50_CD %_NN interest_NN in_IN 10_CD East_NNP 63rd_NNP Street_NNP Inc._NNP the_DT company_NN which_WDT owns_VBZ 10_CD East_NNP 63rd_NNP Street_NNP ,_, a_DT property_NN in_IN New_NNP York_NNP ._.
In_IN December_NNP 2002_CD Mr._NNP Gowrie-Smith_NNP acquired_VBD the_DT remaining_VBG 50_CD %_NN interest_NN ._.
SkyePharma_NNP PLC_NNP has_VBZ been_VBN in_IN occupation_NN of_IN that_DT property_NN since_IN January_NNP 1997_CD ,_, subject_JJ to_TO tenancy_NN agreements_NNS based_VBN upon_IN independent_JJ valuation_NN ._.
In_IN August_NNP 2003_CD the_DT company_NN took_VBD occupation_NN of_IN the_DT entire_JJ building_NN under_IN an_DT eight-year_JJ tenancy_NN agreement_NN ,_, at_IN which_WDT time_NN the_DT annual_JJ rent_NN was_VBD increased_VBN from_IN $_$ 420,000_CD per_IN annum_NN to_TO $_$ 720,000_CD per_IN annum_NN until_IN August_NNP 2008_CD ,_, and_CC $_$ 942,500_CD per_IN annum_NN from_IN August_NNP 2008_CD to_TO August_NNP 2011_CD ._.
28_CD Acquisition_NNP of_IN drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP On_IN 13_CD May_NNP 2002_CD SkyePharma_NNP acquired_VBD the_DT entire_JJ drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP ,_, of_IN Sweden_NNP ,_, for_IN 3.6_CD million_CD in_IN cash_NN including_VBG acquisition_NN costs_NNS and_CC the_DT assumption_NN of_IN 0.4_CD million_CD of_IN net_JJ liabilities_NNS ._.
The_DT acquired_VBN rights_NNS include_VBP Bioglans_NNP Biosphere_NNP injectable_JJ technology_NN and_CC those_DT rights_NNS to_TO DermaStick_NNP ,_, Crystalip_NNP and_CC ES-Gel_NNP topical_JJ drug_NN delivery_NN technologies_NNS that_WDT remained_VBD with_IN Bioglan_NNP after_IN the_DT January_NNP 2001_CD development_NN and_CC commercialisation_NN licensing_NN agreement_NN ._.
The_DT acquisition_NN method_NN was_VBD adopted_VBN and_CC goodwill_NN of_IN 4.0_CD million_CD arose_VBD on_IN the_DT acquisition_NN ._.
By_IN consideration_NN of_IN the_DT likely_JJ commercial_JJ life_NN of_IN the_DT technology_NN acquired_VBN ,_, the_DT Directors_NNS determined_VBD that_IN a_DT suitable_JJ period_NN over_IN which_WDT to_TO amortise_VB the_DT goodwill_NN was_VBD 20_CD years_NNS ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 84_CD 85_CD notes_NNS to_TO the_DT financial_JJ statements_NNS continued_VBD 28_CD Acquisition_NNP of_IN drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP continued_VBD Book_NNP values_NNS and_CC fair_JJ values_NNS 000_CD Fixed_JJ assets_NNS Tangible_JJ assets_NNS 676_CD Current_JJ assets_NNS Debtors_NNS 44_CD Creditors_NNS amounts_VBZ falling_VBG due_JJ within_IN one_CD year_NN 1,095_CD Net_JJ current_JJ liabilities_NNS 1,051_CD Net_JJ liabilities_NNS 375_CD Satisfied_VBN by_IN :_: Cash_NN 3,500_CD Expenses_NNS relating_VBG to_TO the_DT transaction_NN 95_CD Consideration_NNP 3,595_CD Goodwill_NNP 3,970_CD Results_NNS of_IN the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP The_NNP drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP prior_RB to_TO the_DT acquisition_NN formed_VBD part_NN of_IN Bioglan_NNP AB_NNP and_CC did_VBD not_RB report_VB as_IN a_DT separate_JJ unit_NN ._.
During_IN the_DT period_NN 13_CD May_NNP 2002_CD to_TO 31_CD December_NNP 2002_CD the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP contributed_VBD 0.5_CD million_CD to_TO turnover_NN ,_, a_DT loss_NN of_IN 1.5_CD million_CD to_TO operating_VBG profit_NN and_CC a_DT cash_NN outflow_NN of_IN 1.3_CD million_CD to_TO net_JJ cash_NN inflow_NN from_IN operating_VBG activities_NNS ._.
29_CD Subsequent_JJ events_NNS In_IN April_NNP 2004_CD the_DT Group_NNP issued_VBD 20_CD million_CD 6_CD %_NN convertible_JJ bonds_NNS ,_, with_IN a_DT first_RB put_VBN after_IN five_CD years_NNS by_IN the_DT holder_NN of_IN the_DT bonds_NNS ,_, and_CC a_DT final_JJ maturity_NN of_IN May_NNP 2024_CD ._.
The_DT bonds_NNS are_VBP convertible_JJ at_IN the_DT option_NN of_IN the_DT holder_NN into_IN SkyePharma_NNP Ordinary_NNP Shares_NNP at_IN a_DT conversion_NN price_NN of_IN 1.00_CD at_IN any_DT time_NN prior_RB to_TO maturity_NN ._.
Unless_IN previously_RB redeemed_VBN or_CC converted_VBN ,_, the_DT bonds_NNS will_MD be_VB redeemed_VBN by_IN the_DT Group_NNP at_IN their_PRP$ principal_JJ amount_NN in_IN May_NNP 2024_CD ._.
The_DT convertible_JJ bonds_NNS existing_VBG at_IN 31_CD December_NNP 2003_CD ,_, due_RB in_IN June_NNP 2005_CD ,_, are_VBP not_RB affected_VBN by_IN this_DT transaction_NN ._.
30_CD Principal_NN subsidiary_NN undertakings_NNS %_NN held_VBN of_IN nominal_JJ Company_NN Country_NN of_IN incorporation_NN value_NN and_CC voting_NN rights_NNS Principal_NN activities_NNS SkyePharma_NNP Canada_NNP Inc._NNP ._.
Canada_NNP 100_CD %_NN Research_NN and_CC development_NN SkyePharma_NNP Production_NNP SAS_NNP France_NNP 100_CD %_NN Manufacturing_NNP of_IN pharmaceuticals_NNS Krypton_NNP Limited_NNP Gibraltar_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN SkyePharma_NNP AB_NNP Sweden_NNP 100_CD %_NN Research_NN and_CC development_NN Jago_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN Jagotec_NNP AG_NNP Switzerland_NNP 100_CD %_NN Exploitation_NN of_IN intellectual_JJ property_NN SkyePharma_NNP AG_NNP Switzerland_NNP 100_CD %_NN Research_NN and_CC development_NN SkyePharma_NNP Holding_NNP AG_NNP Switzerland_NNP 100_CD %_NN Holding_VBG company_NN SkyePharma_NNP Holding_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Holding_VBG company_NN SkyePharma_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS SkyePharma_NNP US_NNP Inc._NNP ._.
US_NNP 100_CD %_NN Development_NNP of_IN pharmaceuticals_NNS and_CC licensing_NN Directly_RB held_VBN by_IN the_DT Company_NN ._.
Full_JJ details_NNS of_IN all_DT subsidiary_NN undertakings_NNS will_MD be_VB attached_VBN to_TO the_DT Companys_NNP Annual_JJ Return_NN to_TO be_VB filed_VBN with_IN the_DT Registrar_NNP of_IN Companies_NNS ._.
